question,correct_answer,model_output,extracted_info,correct,urls
"Find/search the clinical trial id that best describes the efficacy of Enzalutamide monotherapy compared to Placebo when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT02294461,"The clinical trial that best describes the efficacy of enzalutamide monotherapy compared to placebo in treating prostate cancer is identified by the ClinicalTrials.gov number NCT02319837. This Phase 3 study, known as the EMBARK trial, evaluated enzalutamide monotherapy in patients with high-risk biochemical recurrence of prostate cancer. The results demonstrated that enzalutamide monotherapy significantly delayed metastasis-free survival compared to placebo plus leuprolide acetate. ([oncologypro.esmo.org](https://oncologypro.esmo.org/meeting-resources/esmo-congress-2023/enzalutamide-enza-monotherapy-for-the-treatment-tx-of-prostate-cancer-with-high-risk-biochemical-recurrence-bcr-embark-secondary-endpoints?utm_source=openai)) ",NCT02319837,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP) and Figitumumab compared to Carboplatin and Paclitaxel (CP) when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT00596830,The clinical trial that evaluated the efficacy of Carboplatin and Paclitaxel (CP) in combination with Figitumumab compared to CP alone in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT00615717. ,NCT00615717,False,
"Find/search the clinical trial id that best describes the efficacy of Gemcitabine monotherapy compared to Cisplatin and Gemcitabine (GC) when used to treat Cholangiocarcinoma.
Output it in the format NCT<Number>",NCT00262769,The clinical trial that best describes the efficacy of gemcitabine monotherapy compared to the combination of cisplatin and gemcitabine in treating cholangiocarcinoma is identified by the ClinicalTrials.gov identifier NCT00262769. This study demonstrated that the combination therapy significantly improved overall survival compared to gemcitabine alone. ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa0908721?utm_source=openai)) ,NCT00262769,True,
"Find/search the clinical trial id that best describes the efficacy of CMF compared to Goserelin and Tamoxifen when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00309478,"The clinical trial that best describes the efficacy of CMF (Cyclophosphamide, Methotrexate, and Fluorouracil) compared to the combination of Goserelin and Tamoxifen in treating breast cancer is the Austrian Breast and Colorectal Cancer Study Group Trial 5. This trial demonstrated that the combination of Goserelin and Tamoxifen was significantly more effective than CMF in the adjuvant treatment of premenopausal patients with hormone-responsive breast cancer. ([ascopubs.org](https://ascopubs.org/doi/10.1200/JCO.2002.09.112?utm_source=openai))

However, this study does not have a ClinicalTrials.gov identifier (NCT number) as it was conducted before the widespread adoption of the ClinicalTrials.gov registry. Therefore, there is no NCT number associated with this trial. ",,False,
"Find/search the clinical trial id that best describes the efficacy of Abiraterone and Apalutamide compared to Abiraterone monotherapy when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT02257736,"The clinical trial that evaluates the efficacy of abiraterone acetate and apalutamide, both alone and in combination, compared to abiraterone acetate plus androgen deprivation therapy (ADT) in patients with advanced prostate cancer is registered under the identifier NCT02867020. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31122212/?utm_source=openai)) ",NCT02867020,False,
"Find/search the clinical trial id that best describes the efficacy of Apixaban monotherapy compared to Enoxaparin monotherapy when used to treat Venous thromboembolism.
Output it in the format NCT<Number>",NCT00452530,"The clinical trial that best describes the efficacy of apixaban monotherapy compared to enoxaparin monotherapy in the treatment of venous thromboembolism is identified by ClinicalTrials.gov number NCT00643201. This trial, known as the AMPLIFY study, evaluated the use of apixaban as a single-agent therapy against the conventional treatment regimen of enoxaparin followed by warfarin in patients with acute venous thromboembolism. The results demonstrated that apixaban was noninferior to conventional therapy in preventing recurrent symptomatic venous thromboembolism or death related to venous thromboembolism, with significantly less bleeding. ([nejm.org](https://www.nejm.org/doi/full/10.1056/nejmoa1302507?utm_source=openai)) ",NCT00643201,False,
"Find/search the clinical trial id that best describes the efficacy of Apixaban monotherapy compared to Enoxaparin monotherapy when used to treat Venous thromboembolism.
Output it in the format NCT<Number>",NCT00423319,"The clinical trial that best describes the efficacy of Apixaban monotherapy compared to Enoxaparin monotherapy in treating venous thromboembolism is identified by the ClinicalTrials.gov identifier NCT00643201. This trial, known as ADVANCE-2, was a randomized, double-blind study that evaluated the effectiveness of Apixaban versus Enoxaparin for thromboprophylaxis after knee replacement surgery. ([de.wikipedia.org](https://de.wikipedia.org/wiki/Apixaban?utm_source=openai)) ",NCT00643201,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Pemetrexed|Cisplatin and Pemetrexed compared to Cisplatin, Pemetrexed, Durvalumab when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT03800134,"The clinical trial that best describes the efficacy of Carboplatin and Pemetrexed or Cisplatin and Pemetrexed compared to Cisplatin, Pemetrexed, and Durvalumab in treating nonsquamous non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT03519971. ([astrazenecaclinicaltrials.com](https://www.astrazenecaclinicaltrials.com/study/D933KC00001/?utm_source=openai)) ",NCT03519971,False,
"Find/search the clinical trial id that best describes the efficacy of Enzalutamide monotherapy compared to Placebo when used to treat Prostate cancer (Metastatic).
Output it in the format NCT<Number>",NCT00974311,"The clinical trial that best describes the efficacy of enzalutamide monotherapy compared to placebo in treating metastatic prostate cancer is identified by the ClinicalTrials.gov number NCT01212991. This trial, known as the PREVAIL study, was a double-blind, phase 3 study involving 1,717 patients with metastatic castration-resistant prostate cancer who had not received prior chemotherapy. The results demonstrated that enzalutamide significantly decreased the risk of radiographic progression and death, and delayed the initiation of chemotherapy in these patients. ([nejm.org](https://www.nejm.org/doi/full/10.1056/nejmoa1405095?utm_source=openai)) ",NCT01212991,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP) compared to Carboplatin and Paclitaxel (CP) and Penpulimab when used to treat Non-small cell lung cancer squamous (Locally Advanced or Metastatic).
Output it in the format NCT<Number>",NCT03866993,"I couldn't locate a clinical trial specifically comparing the efficacy of Carboplatin and Paclitaxel (CP) alone versus CP combined with Penpulimab for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) of the squamous subtype. However, a related study, identified as NCT02775435, evaluated the combination of CP with Pembrolizumab in this patient population. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT02775435?utm_source=openai))

Penpulimab is a PD-1 inhibitor similar to Pembrolizumab, so the findings from NCT02775435 may offer relevant insights. For the most current information on clinical trials involving Penpulimab, I recommend consulting the ClinicalTrials.gov database or discussing with a healthcare professional. ",NCT02775435,False,
"Find/search the clinical trial id that best describes the efficacy of Alectinib monotherapy compared to Crizotinib monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT02838420,The clinical trial that best describes the efficacy of alectinib monotherapy compared to crizotinib monotherapy in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT02075840. ([nejm.org](https://www.nejm.org/doi/10.1056/NEJMoa1704795?utm_source=openai)) ,NCT02075840,False,
"Find/search the clinical trial id that best describes the efficacy of Sunitinib monotherapy compared to Everolimus monotherapy when used to treat Non-clear cell renal cell carcinoma.
Output it in the format NCT<Number>",NCT01108445,The clinical trial that best describes the efficacy of sunitinib monotherapy compared to everolimus monotherapy in treating non-clear cell renal cell carcinoma is identified by the ClinicalTrials.gov identifier NCT01108445. ([ascopubs.org](https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.4507?utm_source=openai)) ,NCT01108445,True,
"Find/search the clinical trial id that best describes the efficacy of Tranexamic acid monotherapy compared to Placebo when used to treat Hereditary hemorrhagic telangiectasia.
Output it in the format NCT<Number>",NCT00355108,The clinical trial that best describes the efficacy of tranexamic acid monotherapy compared to placebo in treating hereditary hemorrhagic telangiectasia is registered under the identifier NCT01031992. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01031992?utm_source=openai)) ,NCT01031992,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Pemetrexed compared to ABCP when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT03991403,"The clinical trial that best describes the efficacy of Carboplatin and Pemetrexed compared to ABCP (Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel) in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT00762034. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24145346/?utm_source=openai)) ",NCT00762034,False,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide and Rituximab (R2) compared to Rituximab monotherapy when used to treat Follicular lymphoma.
Output it in the format NCT<Number>",NCT01938001,The clinical trial that best describes the efficacy of Lenalidomide and Rituximab (R²) compared to Rituximab monotherapy in treating follicular lymphoma is identified by the ClinicalTrials.gov identifier NCT01996865. ([ashpublications.org](https://ashpublications.org/blood/article/124/21/799/101805/Rituximab-Plus-Lenalidomide-Improves-the-Complete?utm_source=openai)) ,NCT01996865,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Docetaxel and Bevacizumab when used to treat Breast cancer (Not Applicable).
Output it in the format NCT<Number>",NCT00333775,The clinical trial that best describes the efficacy of docetaxel monotherapy compared to docetaxel combined with bevacizumab in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT00333775. ([ascopubs.org](https://ascopubs.org/doi/full/10.1200/JCO.2008.21.6457?utm_source=openai)) ,NCT00333775,True,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Trastuzumab (TH) compared to BTH (Docetaxel) when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00391092,"The clinical trial that best describes the efficacy of Docetaxel and Trastuzumab (TH) compared to Docetaxel alone in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT00045971. This randomized, multicenter phase II trial evaluated the combination of trastuzumab and docetaxel versus docetaxel alone in patients with HER2-positive metastatic breast cancer. The study found that the combination therapy was significantly superior in terms of overall response rate, overall survival, time to disease progression, time to treatment failure, and duration of response, with little additional toxicity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15911866/?utm_source=openai)) ",NCT00045971,False,
"Find/search the clinical trial id that best describes the efficacy of Low-dose Cytarabine monotherapy (LoDAC) compared to Azacitidine monotherapy when used to treat Acute myeloid leukemia.
Output it in the format NCT<Number>",NCT00071799,"The clinical trial that best describes the efficacy of low-dose cytarabine (LoDAC) monotherapy compared to azacitidine monotherapy in the treatment of acute myeloid leukemia is identified by the ClinicalTrials.gov identifier NCT01074047. This Phase 3, multicenter, randomized, open-label study compared azacitidine (Vidaza®) to conventional care regimens, including low-dose cytarabine, in older subjects with newly diagnosed acute myeloid leukemia. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01074047?utm_source=openai)) ",NCT01074047,False,
"Find/search the clinical trial id that best describes the efficacy of Enzalutamide monotherapy compared to Abiraterone and Enzalutamide when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT01949337,"The clinical trial that best describes the efficacy of enzalutamide monotherapy compared to the combination of enzalutamide and abiraterone in treating metastatic castration-resistant prostate cancer is identified by the ClinicalTrials.gov identifier NCT01949337. This Phase III study, known as the Alliance A031201 Trial, evaluated whether adding abiraterone acetate and prednisone to enzalutamide would prolong overall survival in patients with untreated metastatic castration-resistant prostate cancer. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36996380/?utm_source=openai)) ",NCT01949337,True,
"Find/search the clinical trial id that best describes the efficacy of Blinatumomab monotherapy compared to Standard salvage consolidation chemotherapy when used to treat B-cell acute lymphoblastic leukemia pediatric.
Output it in the format NCT<Number>",NCT02393859,The clinical trial that best describes the efficacy of blinatumomab monotherapy compared to standard salvage consolidation chemotherapy in treating pediatric B-cell acute lymphoblastic leukemia is identified by the ClinicalTrials.gov identifier NCT02393859. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33651091/?utm_source=openai)) ,NCT02393859,True,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP) and Bevacizumab compared to Carboplatin and Paclitaxel (CP) when used to treat Melanoma.
Output it in the format NCT<Number>",NCT02023710,The clinical trial that best describes the efficacy of Carboplatin and Paclitaxel (CP) with Bevacizumab compared to CP alone in treating melanoma is identified by the ClinicalTrials.gov identifier NCT02023710. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33444116/?utm_source=openai)) ,NCT02023710,True,
"Find/search the clinical trial id that best describes the efficacy of AC-TH (Docetaxel) compared to AC-D when used to treat Breast cancer (Node Positive).
Output it in the format NCT<Number>",NCT00021255,"The clinical trial that best describes the efficacy of AC-TH (Doxorubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab) compared to AC-D (Doxorubicin and Cyclophosphamide followed by Docetaxel) in treating node-positive breast cancer is identified by the ClinicalTrials.gov identifier NCT00021255. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT00021255/?utm_source=openai))

This Phase III trial, sponsored by Sanofi, aimed to compare disease-free survival among women with HER2-positive, node-positive, or high-risk node-negative operable breast cancer treated with adjuvant AC-T (Doxorubicin and Cyclophosphamide followed by Docetaxel) with or without Trastuzumab, and with TCH (Docetaxel, Carboplatin, and Trastuzumab). ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT00021255/?utm_source=openai))

The study enrolled 3,222 participants and was completed in December 2014. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT00021255/?utm_source=openai)) ",NCT00021255,True,
"Find/search the clinical trial id that best describes the efficacy of FOLFIRI and Bevacizumab compared to FOLFIRI when used to treat Colorectal cancer.
Output it in the format NCT<Number>",NCT00720512,"The clinical trial that best describes the efficacy of FOLFIRI plus Bevacizumab compared to FOLFIRI alone in treating colorectal cancer is identified by the ClinicalTrials.gov identifier NCT00719797. This trial, known as the TRIBE study, evaluated the combination of FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus Bevacizumab versus FOLFIRI plus Bevacizumab as first-line treatment for metastatic colorectal cancer. The results demonstrated that the FOLFOXIRI plus Bevacizumab regimen significantly improved progression-free survival and overall survival compared to the FOLFIRI plus Bevacizumab regimen. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26338525/?utm_source=openai)) ",NCT00719797,False,
"Find/search the clinical trial id that best describes the efficacy of Bortezomib and Dexamethasone (Vd) compared to Bortezomib and Dexamethasone (Vd) and Venetoclax when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT02755597,"The clinical trial that best describes the efficacy of Bortezomib and Dexamethasone (Vd) compared to Bortezomib, Dexamethasone, and Venetoclax (Vd+Venetoclax) in treating multiple myeloma is identified by the ClinicalTrials.gov identifier NCT02755597. This Phase 3, multicenter, randomized, double-blind study evaluated the efficacy and safety of adding Venetoclax to the standard Vd regimen in patients with relapsed or refractory multiple myeloma. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33129376/?utm_source=openai)) ",NCT02755597,True,
"Find/search the clinical trial id that best describes the efficacy of Paclitaxel monotherapy compared to Buparlisib and Paclitaxel when used to treat Head and neck cancer.
Output it in the format NCT<Number>",NCT01852292,"The clinical trial that best describes the efficacy of paclitaxel monotherapy compared to the combination of buparlisib and paclitaxel in treating head and neck cancer is identified by the ClinicalTrials.gov identifier NCT01852292. ([dana-farber.org](https://www.dana-farber.org/clinical-trials/13-461?utm_source=openai))

This Phase II, multicenter, randomized, double-blind, placebo-controlled study assessed the efficacy and safety of buparlisib (BKM120) plus paclitaxel versus placebo plus paclitaxel in patients with platinum-pretreated recurrent or metastatic head and neck squamous cell carcinoma. ([ascopubs.org](https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.6008?utm_source=openai))

The study demonstrated that the combination of buparlisib and paclitaxel improved progression-free survival compared to paclitaxel alone, suggesting potential benefits of the combination therapy in this patient population. ([ascopost.com](https://ascopost.com/issues/april-25-2017/addition-of-buparlisib-to-paclitaxel-in-squamous-cell-carcinoma-of-the-head-and-neck/?utm_source=openai)) ",NCT01852292,True,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP) and Bevacizumab compared to Carboplatin and Paclitaxel (CP) when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT01364012,The clinical trial that best describes the efficacy of Carboplatin and Paclitaxel (CP) with Bevacizumab compared to CP alone in treating nonsquamous non-small-cell lung cancer is identified by the ClinicalTrials.gov number NCT00021060. This randomized study demonstrated that adding Bevacizumab to CP significantly improved overall survival and progression-free survival in patients with advanced non-small-cell lung cancer. ([nejm.org](https://www.nejm.org/doi/full/10.1056/nejmoa061884?utm_source=openai)) ,NCT00021060,False,
"Find/search the clinical trial id that best describes the efficacy of Bortezomib and Dexamethasone (Vd) compared to SVd when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT03110562,"The clinical trial that best describes the efficacy of Bortezomib and Dexamethasone (Vd) compared to Selinexor, Bortezomib, and Dexamethasone (SVd) in treating multiple myeloma is identified by the ClinicalTrials.gov identifier NCT04939142. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT04939142?utm_source=openai)) ",NCT04939142,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Vemurafenib monotherapy when used to treat Melanoma.
Output it in the format NCT<Number>",NCT01667419,The clinical trial that best describes the efficacy of vemurafenib monotherapy compared to placebo in treating melanoma is identified by the ClinicalTrials.gov identifier NCT01667419. ([mycancergenome.org](https://www.mycancergenome.org/content/clinical_trials/NCT01667419/?utm_source=openai)) ,NCT01667419,True,
"Find/search the clinical trial id that best describes the efficacy of ATRA, Mercaptopurine, Methotrexate compared to ATRA monotherapy when used to treat Acute promyelocytic leukemia.
Output it in the format NCT<Number>",NCT00003934,"The clinical trial that best describes the efficacy of adding mercaptopurine and methotrexate to all-trans retinoic acid (ATRA) maintenance therapy compared to ATRA monotherapy in treating acute promyelocytic leukemia (APL) is identified by the ClinicalTrials.gov identifier NCT00003934. This study, known as the North American Leukemia Intergroup Trial C9710, evaluated whether the addition of mercaptopurine and methotrexate to alternate-week ATRA maintenance therapy improved outcomes for adults with APL in first remission. The results indicated that this combination did not significantly enhance disease-free or overall survival compared to ATRA alone. ([ashpublications.org](https://ashpublications.org/blood/article/118/21/258/70220/Adding-Mercaptopurine-and-Methotrexate-to?utm_source=openai)) ",NCT00003934,True,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and nab-Paclitaxel compared to Carboplatin and Paclitaxel (CP) when used to treat Non-small cell lung cancer (Locally Advanced or Metastatic).
Output it in the format NCT<Number>",NCT00540514,The clinical trial that best describes the efficacy of Carboplatin and nab-Paclitaxel compared to Carboplatin and Paclitaxel in treating locally advanced or metastatic non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT00540514. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/22547591/?utm_source=openai)) ,NCT00540514,True,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP) and Ipilimumab compared to Carboplatin and Paclitaxel (CP) when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT00527735,The clinical trial that best describes the efficacy of Carboplatin and Paclitaxel (CP) combined with Ipilimumab compared to CP alone in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT01285609. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28854067/?utm_source=openai)) ,NCT01285609,False,
"Find/search the clinical trial id that best describes the efficacy of Elo-Vd compared to Bortezomib and Dexamethasone (Vd) when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01478048,The clinical trial that best describes the efficacy of elotuzumab in combination with bortezomib and dexamethasone (Elo-Vd) compared to bortezomib and dexamethasone (Vd) in treating multiple myeloma is registered under the identifier NCT02718833. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39626297/?utm_source=openai)) ,NCT02718833,False,
"Find/search the clinical trial id that best describes the efficacy of Paclitaxel, nanoparticle albumin-bound and Bevacizumab compared to Paclitaxel and Bevacizumab when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00785291,"I couldn't locate a specific clinical trial comparing the efficacy of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) combined with bevacizumab versus paclitaxel combined with bevacizumab in the treatment of breast cancer. However, there are notable studies involving these combinations:

- **E2100 Trial**: This Phase III trial evaluated the combination of paclitaxel and bevacizumab in women with metastatic breast cancer. ([de.wikipedia.org](https://de.wikipedia.org/wiki/Bevacizumab?utm_source=openai))

- **RIBBON-1 Trial**: This randomized, double-blind, placebo-controlled Phase III trial assessed chemotherapy with or without bevacizumab for first-line treatment of HER2-negative, locally recurrent, or metastatic breast cancer. ([de.wikipedia.org](https://de.wikipedia.org/wiki/Bevacizumab?utm_source=openai))

For the most current and detailed information, I recommend searching the ClinicalTrials.gov database using keywords like ""nab-paclitaxel,"" ""bevacizumab,"" and ""breast cancer"" to identify relevant clinical trials. ",,False,
"Find/search the clinical trial id that best describes the efficacy of T-ddAC compared to T-ddAC and Bevacizumab when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00861705,The clinical trial that best describes the efficacy of T-ddAC (weekly paclitaxel followed by dose-dense doxorubicin and cyclophosphamide) compared to T-ddAC combined with Bevacizumab in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT00861705. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25092775/?utm_source=openai)) ,NCT00861705,True,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide monotherapy compared to Lenalidomide and Rituximab (R2) when used to treat Follicular lymphoma.
Output it in the format NCT<Number>",NCT00238238,"The clinical trial that best describes the efficacy of Lenalidomide monotherapy compared to Lenalidomide plus Rituximab (R2) in treating follicular lymphoma is identified by the ClinicalTrials.gov identifier NCT00540007. This study, known as CALGB 50401 (Alliance), was a randomized trial that evaluated these treatments in patients with recurrent follicular lymphoma. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26304886/?utm_source=openai)) ",NCT00540007,False,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin and Gemcitabine (GC) and Bevacizumab compared to Cisplatin and Gemcitabine (GC) when used to treat Urothelial carcinoma.
Output it in the format NCT<Number>",NCT00942331,The clinical trial that best describes the efficacy of Cisplatin and Gemcitabine (GC) combined with Bevacizumab compared to GC alone in treating urothelial carcinoma is registered under the identifier NCT00942331. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33989025/?utm_source=openai)) ,NCT00942331,True,
"Find/search the clinical trial id that best describes the efficacy of FULV compared to Hepatic arterial chemotherapy when used to treat Colorectal cancer.
Output it in the format NCT<Number>",NCT00002716,"I couldn't locate a clinical trial that directly compares the efficacy of FULV (fluorouracil and leucovorin) to hepatic arterial infusion chemotherapy in treating colorectal cancer. However, several studies have evaluated hepatic arterial infusion chemotherapy in this context:

1. **NCT02494973**: This randomized phase II/III trial, known as PACHA-01, investigates postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9243466/?utm_source=openai))

2. **NCT02557490**: This randomized phase II trial compares hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases. ([frontiersin.org](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.913017/full?utm_source=openai))

While these trials focus on hepatic arterial infusion chemotherapy, they do not provide a direct comparison to FULV. For more detailed information, you may refer to the respective clinical trial records. ",NCT02494973,False,
"Find/search the clinical trial id that best describes the efficacy of ddAC-ddT compared to A-T-C when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00003088,"The clinical trial that best describes the efficacy of dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel (ddAC-ddT) compared to doxorubicin, cyclophosphamide, and paclitaxel (A-T-C) in treating breast cancer is registered under the identifier NCT05256745. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT05256745?utm_source=openai))

This study, titled ""RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (RAGE),"" is a pilot study evaluating the effects of azeliragon in reducing cardiac toxicity from chemotherapy and assessing its safety when administered with chemotherapy. The trial includes cohorts receiving ddAC followed by ddT and TC regimens.

Another relevant study is the ""High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial,"" registered under NCT01057069. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37689749/?utm_source=openai)) This trial investigates the efficacy of high-dose chemotherapy regimens, including ddAC, in patients with BRCA-altered triple-negative breast cancer.

These trials provide insights into the comparative efficacy and safety of ddAC-ddT and A-T-C regimens in breast cancer treatment. ",NCT05256745,False,
"Find/search the clinical trial id that best describes the efficacy of Pomalidomide and Dexamethasone (Pd) compared to Pomalidomide monotherapy when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00833833,The clinical trial that best describes the efficacy of Pomalidomide and Dexamethasone (Pd) compared to Pomalidomide monotherapy in treating multiple myeloma is registered under the identifier NCT00833833. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24421329/?utm_source=openai)) ,NCT00833833,True,
"Find/search the clinical trial id that best describes the efficacy of Mercaptopurine, Methotrexate, Vincristine compared to Mercaptopurine, Methotrexate, Pegaspargase, Vincristine when used to treat B-cell acute lymphoblastic leukemia pediatric.
Output it in the format NCT<Number>",NCT00075725,"I couldn't locate a clinical trial that directly compares the efficacy of the chemotherapy regimens Mercaptopurine, Methotrexate, Vincristine versus Mercaptopurine, Methotrexate, Pegaspargase, Vincristine in treating pediatric B-cell acute lymphoblastic leukemia (ALL). However, I found information on a related clinical trial:

- **NCT01574274**: This trial evaluated the pharmacokinetics of calaspargase pegol-mknl (a form of asparaginase) in combination with multi-agent chemotherapy in pediatric and young adult patients with B-cell lineage ALL. While it doesn't directly compare the two regimens you're interested in, it provides insights into the use of asparaginase formulations in ALL treatment. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Calaspargase_pegol?utm_source=openai))

For more detailed information, you can refer to the clinical trial registry or consult with a healthcare professional specializing in pediatric oncology. ",NCT01574274,False,
"Find/search the clinical trial id that best describes the efficacy of Blinatumomab monotherapy compared to Standard salvage consolidation chemotherapy when used to treat B-cell acute lymphoblastic leukemia.
Output it in the format NCT<Number>",NCT02101853,The clinical trial that best describes the efficacy of blinatumomab monotherapy compared to standard salvage consolidation chemotherapy in treating B-cell acute lymphoblastic leukemia is identified by the ClinicalTrials.gov identifier NCT02013167. ([nejm.org](https://www.nejm.org/doi/10.1056/NEJMoa1609783?utm_source=openai)) ,NCT02013167,False,
"Find/search the clinical trial id that best describes the efficacy of COG ANBL0532 Regimen A compared to COG ANBL0532 Regimen B when used to treat Neuroblastoma.
Output it in the format NCT<Number>",NCT00567567,The clinical trial that best describes the efficacy of COG ANBL0532 Regimen A compared to COG ANBL0532 Regimen B in treating neuroblastoma is identified by the ClinicalTrials.gov identifier NCT00567567. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32530765/?utm_source=openai)) ,NCT00567567,True,
"Find/search the clinical trial id that best describes the efficacy of Mercaptopurine, Methotrexate, Vincristine, Dexamethasone compared to Methotrexate and Vincristine when used to treat B-cell acute lymphoblastic leukemia pediatric.
Output it in the format NCT<Number>",NCT00005945,"I couldn't locate a specific clinical trial with an NCT number that directly compares the efficacy of the combination of mercaptopurine, methotrexate, vincristine, and dexamethasone to methotrexate and vincristine alone in treating pediatric B-cell acute lymphoblastic leukemia (ALL). However, historical data indicates that combination chemotherapy regimens, such as the VAMP regimen (vincristine, amethopterin [methotrexate], mercaptopurine, and prednisone), have been instrumental in achieving long-term remissions in children with ALL. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Emil_J._Freireich?utm_source=openai))

For the most current and specific clinical trial information, I recommend searching the ClinicalTrials.gov database using relevant keywords or consulting with a healthcare professional specializing in pediatric oncology. ",,False,
"Find/search the clinical trial id that best describes the efficacy of Best supportive care compared to Docetaxel monotherapy when used to treat Esophageal adenocarcinoma.
Output it in the format NCT<Number>",NCT00978549,"The clinical trial that best describes the efficacy of best supportive care compared to docetaxel monotherapy in treating esophageal adenocarcinoma is identified by the ClinicalTrials.gov identifier NCT01014493. This Phase III randomized controlled trial evaluated the effectiveness of docetaxel plus best supportive care versus best supportive care alone in patients with relapsed esophageal, gastroesophageal junction, and gastric adenocarcinoma. The study demonstrated that chemotherapy with docetaxel significantly reduced the risk of death compared to supportive care alone. ([nature.com](https://www.nature.com/articles/bjc2015452?code=0cfe0de3-7211-4232-9191-91b8e414d671&error=cookies_not_supported&utm_source=openai)) ",NCT01014493,False,
"Find/search the clinical trial id that best describes the efficacy of Rituximab monotherapy compared to Ibrutinib monotherapy when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT01973387,"The clinical trial that directly compares the efficacy of Rituximab monotherapy to Ibrutinib monotherapy in treating chronic lymphocytic leukemia (CLL) is registered under the identifier NCT01973387. This randomized, open-label, phase 3 study evaluated the efficacy and safety of Ibrutinib versus Rituximab in adult patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL). ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01973387?utm_source=openai)) ",NCT01973387,True,
"Find/search the clinical trial id that best describes the efficacy of Capecitabine and Gemcitabine compared to Gemcitabine monotherapy when used to treat Pancreatic cancer.
Output it in the format NCT<Number>",NCT00032175,"The clinical trial that best describes the efficacy of Capecitabine and Gemcitabine compared to Gemcitabine monotherapy in treating pancreatic cancer is identified by the ClinicalTrials.gov identifier NCT00058201. This phase III randomized study evaluated the combination of Gemcitabine and Capecitabine versus Gemcitabine alone in patients with advanced pancreatic cancer. The results indicated that while the combination therapy improved progression-free survival and response rates, it did not achieve a statistically significant improvement in overall survival compared to Gemcitabine monotherapy. ([ascopubs.org](https://ascopubs.org/doi/10.1200/JCO.2009.24.2446?utm_source=openai)) ",NCT00058201,False,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin and Pemetrexed compared to Carboplatin, Pemetrexed, Nivolumab|Cisplatin, Pemetrexed, Nivolumab when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT02864251,"The PARAMOUNT trial (NCT00789373) investigated the efficacy of maintenance therapy with pemetrexed following initial treatment with pemetrexed and cisplatin in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ([en.wikipedia.org](https://en.wikipedia.org/wiki/PARAMOUNT_trial?utm_source=openai)) However, this trial did not include comparisons involving carboplatin, nivolumab, or combinations thereof.

The CHECKMATE-227 trial evaluated the combination of nivolumab and ipilimumab in patients with stage IV or recurrent NSCLC, comparing it to chemotherapy regimens that included cisplatin or carboplatin combined with gemcitabine or pemetrexed. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Nivolumab?utm_source=openai)) While this study involved nivolumab and chemotherapy agents, it did not specifically compare the efficacy of cisplatin and pemetrexed to carboplatin, pemetrexed, and nivolumab.

Based on the available information, there does not appear to be a clinical trial that directly compares the efficacy of cisplatin and pemetrexed to carboplatin, pemetrexed, and nivolumab in the treatment of non-small-cell lung cancer. ",NCT00789373,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Pemetrexed|Cisplatin and Pemetrexed|Carboplatin and Paclitaxel .28CP compared to Cisplatin, Pemetrexed, Nivolumab when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT04025879,"The clinical trial that best matches your criteria is NCT01454102. This study, known as CheckMate 012, evaluated the safety and tolerability of Nivolumab in combination with various chemotherapy regimens, including:

- Cisplatin and Pemetrexed
- Carboplatin and Paclitaxel

The trial focused on patients with Stage IIIB/IV non-small cell lung cancer (NSCLC). ([bmsclinicaltrials.com](https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT01454102?utm_source=openai))

Additionally, the CheckMate 9LA study (NCT03215706) investigated the efficacy of Nivolumab and Ipilimumab combined with chemotherapy versus chemotherapy alone in first-line treatment for Stage IV NSCLC. The chemotherapy regimens included:

- Cisplatin or Carboplatin combined with Pemetrexed or Paclitaxel

This study also aligns with your specified treatments. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT03215706?utm_source=openai))

Therefore, both NCT01454102 and NCT03215706 are relevant to your query. ",NCT01454102,False,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin and Docetaxel (DC) and Nivolumab compared to Carboplatin and Paclitaxel (CP)|Cisplatin and Vinorelbine (CVb)|Cisplatin and Docetaxel (DC) when used to treat Non-small cell lung cancer (Resectable).
Output it in the format NCT<Number>",NCT02998528,"The clinical trial that best describes the efficacy of Cisplatin and Docetaxel (DC) combined with Nivolumab compared to Carboplatin and Paclitaxel (CP), Cisplatin and Vinorelbine (CVb), and Cisplatin and Docetaxel (DC) in treating resectable non-small cell lung cancer (NSCLC) is identified by the ClinicalTrials.gov identifier NCT03800134. This trial, known as AEGEAN, evaluated the use of Durvalumab (a PD-L1 inhibitor similar to Nivolumab) in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by Durvalumab as adjuvant treatment after surgery in adults with resectable NSCLC. The study included various chemotherapy regimens, such as Cisplatin and Docetaxel, to assess their efficacy in combination with immunotherapy. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Durvalumab?utm_source=openai)) ",NCT03800134,False,
"Find/search the clinical trial id that best describes the efficacy of Etoposide monotherapy compared to Lenalidomide monotherapy when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT01197560,"The clinical trial that best describes the efficacy of Etoposide monotherapy compared to Lenalidomide monotherapy in treating Diffuse Large B-Cell Lymphoma (DLBCL) is identified by the ClinicalTrials.gov identifier NCT01197560. This Phase 2/3 multicenter, randomized, open-label study compared Lenalidomide to the investigator's choice of treatment, which included Etoposide among other options, in patients with relapsed or refractory DLBCL. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8171498/?utm_source=openai)) ",NCT01197560,True,
"Find/search the clinical trial id that best describes the efficacy of mDCF compared to Cisplatin and Fluorouracil (CF) when used to treat Gastric cancer.
Output it in the format NCT<Number>",NCT00811447,"The clinical trial that best describes the efficacy of modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) compared to Cisplatin and Fluorouracil (CF) in treating gastric cancer is registered under the identifier NCT00515411. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26438119/?utm_source=openai)) ",NCT00515411,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Pegylated liposomal doxorubicin compared to Docetaxel monotherapy when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00091442,The clinical trial that best describes the efficacy of combining docetaxel with pegylated liposomal doxorubicin compared to docetaxel monotherapy in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT00091442. ([ascopubs.org](https://ascopubs.org/doi/full/10.1200/JCO.2008.20.5013?utm_source=openai)) ,NCT00091442,True,
"Find/search the clinical trial id that best describes the efficacy of Rituximab monotherapy compared to Observation when used to treat Follicular lymphoma.
Output it in the format NCT<Number>",NCT00005589,"The clinical trial that best describes the efficacy of Rituximab monotherapy compared to observation in treating follicular lymphoma is identified by the ClinicalTrials.gov identifier NCT00112931. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00112931?utm_source=openai))

This randomized phase III trial evaluated Rituximab versus a watch-and-wait strategy in patients with newly diagnosed, asymptomatic, advanced-stage follicular non-Hodgkin's lymphoma. The study found that Rituximab monotherapy significantly delayed the need for new therapy compared to observation alone. ([ashpublications.org](https://ashpublications.org/blood/article/116/21/6/66557/An-Intergroup-Randomised-Trial-of-Rituximab-Versus?utm_source=openai)) ",NCT00112931,False,
"Find/search the clinical trial id that best describes the efficacy of Rituximab monotherapy compared to Observation when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT00003204,"I couldn't locate a clinical trial specifically comparing Rituximab monotherapy to observation in the treatment of Chronic Lymphocytic Leukemia (CLL). However, Rituximab is often used in combination with other therapies for CLL. For instance, the clinical trial NCT00281918 evaluated the efficacy of Rituximab in combination with Fludarabine and Cyclophosphamide in treating CLL. If you're interested in exploring clinical trials involving Rituximab for CLL, you can search the ClinicalTrials.gov database using keywords like ""Rituximab"" and ""Chronic Lymphocytic Leukemia."" ",NCT00281918,False,
"Find/search the clinical trial id that best describes the efficacy of Dexamethasone monotherapy compared to Thalidomide and Dexamethasone (TD) when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00033332,The clinical trial that best describes the efficacy of dexamethasone monotherapy compared to thalidomide and dexamethasone (TD) in treating multiple myeloma is registered under the identifier NCT00057564. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18362366/?utm_source=openai)) ,NCT00057564,False,
"Find/search the clinical trial id that best describes the efficacy of VAD and Valspodar compared to VAD when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00002878,"The clinical trial that evaluated the efficacy of VAD (vincristine, doxorubicin, and dexamethasone) with and without Valspodar (PSC-833) in treating multiple myeloma is registered under the identifier NCT00002878. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00002878?utm_source=openai)) ",NCT00002878,True,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide monotherapy compared to Erythropoetin beta and Lenalidomide when used to treat Myelodysplastic syndrome.
Output it in the format NCT<Number>",NCT00843882,"The clinical trial that best describes the efficacy of lenalidomide monotherapy compared to lenalidomide combined with erythropoietin alfa in treating myelodysplastic syndromes is registered under the identifier NCT02048813. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33439748/?utm_source=openai))

In this phase III trial, 195 patients with lower-risk, non-del(5q) myelodysplastic syndromes were randomized to receive either lenalidomide alone or in combination with erythropoietin alfa. The study found that the combination therapy resulted in a significantly higher major erythroid response rate (28.3%) compared to lenalidomide monotherapy (11.5%). Additionally, the median duration of response was longer in the combination group (23.8 months) than in the monotherapy group (13 months). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33439748/?utm_source=openai))

Another relevant study, registered under NCT00843882, evaluated lenalidomide with or without erythropoietin beta in transfusion-dependent, erythropoiesis-stimulating agent-refractory, lower-risk myelodysplastic syndromes without 5q deletion. This phase III study included 131 patients and reported an erythroid response rate of 39.4% in the combination therapy group versus 23.1% in the lenalidomide monotherapy group. However, the difference in red blood cell transfusion independence between the two groups was not statistically significant. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26500139/?utm_source=openai))

These studies suggest that combining lenalidomide with erythropoietin may enhance erythroid response rates in certain patients with myelodysplastic syndromes. ",NCT02048813,False,
"Find/search the clinical trial id that best describes the efficacy of CHOP compared to R-CHOP when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT00003150,"The clinical trial identifier for the study comparing the efficacy of CHOP versus R-CHOP in treating Diffuse Large B-Cell Lymphoma (DLBCL) is NCT01287741. This Phase III, open-label, randomized study, known as the GOYA trial, evaluated the efficacy and safety of obinutuzumab plus CHOP (G-CHOP) versus rituximab plus CHOP (R-CHOP) in previously untreated patients with DLBCL. The final analysis did not demonstrate a progression-free survival benefit of G-CHOP over R-CHOP. ([jhoonline.biomedcentral.com](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00900-7?utm_source=openai)) ",NCT01287741,False,
"Find/search the clinical trial id that best describes the efficacy of AT-CMF compared to A-CMF when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00003013,"I couldn't locate a specific clinical trial with an NCT number that directly compares the efficacy of AT-CMF (doxorubicin, docetaxel, cyclophosphamide, methotrexate, and fluorouracil) to A-CMF (doxorubicin, cyclophosphamide, methotrexate, and fluorouracil) in the treatment of breast cancer. However, studies have evaluated the effectiveness of taxane-containing regimens, such as those including docetaxel, in adjuvant chemotherapy for early breast cancer. These studies have found that taxane-containing regimens improve overall survival and disease-free survival compared to non-taxane regimens. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Breast_cancer_chemotherapy?utm_source=openai))

Additionally, research has compared epirubicin-containing regimens like FEC (fluorouracil, epirubicin, cyclophosphamide) with CMF (cyclophosphamide, methotrexate, fluorouracil) in the adjuvant setting. These studies concluded that FEC is at least as effective as CMF in premenopausal women with node-positive or negative breast cancer, with no additional benefit in terms of 5-year relapse-free or overall survival. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Epirubicin?utm_source=openai))

While these findings suggest the potential benefits of taxane-containing regimens, for detailed information on specific clinical trials, I recommend consulting the ClinicalTrials.gov database or discussing with a healthcare professional. ",,False,
"Find/search the clinical trial id that best describes the efficacy of Irinotecan monotherapy compared to IROX when used to treat Colorectal cancer.
Output it in the format NCT<Number>",NCT00012389,"The clinical trial that best describes the efficacy of irinotecan monotherapy compared to the combination of irinotecan and oxaliplatin (IROX) in treating colorectal cancer is identified by the ClinicalTrials.gov identifier NCT00025337. This phase III, randomized, open-label, multicenter study evaluated patients with metastatic or recurrent colorectal cancer who had progressed or recurred during or after adjuvant or first-line fluoropyrimidine therapy. The trial found that the IROX regimen improved overall survival, response rate, and time to progression compared to irinotecan alone. ([ascopubs.org](https://ascopubs.org/doi/10.1200/JCO.2008.17.1249?utm_source=openai)) ",NCT00025337,False,
"Find/search the clinical trial id that best describes the efficacy of Prednisone monotherapy compared to Orteronel and Prednisone when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT01193244,The clinical trial that best describes the efficacy of prednisone monotherapy compared to orteronel plus prednisone in treating prostate cancer is registered under the identifier NCT01193257. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25624429/?utm_source=openai)) ,NCT01193257,False,
"Find/search the clinical trial id that best describes the efficacy of Tandem melphalan compared to CRd when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01091831,"After reviewing the available clinical trials, I couldn't find a study that directly compares tandem melphalan therapy to the combination of carfilzomib, lenalidomide, and dexamethasone (CRd) in the treatment of multiple myeloma. However, there are several trials that have evaluated the efficacy of tandem melphalan regimens:

- **NCT00205764**: This phase III study compared tandem high-dose melphalan (200 mg/m²) versus triple intermediate-dose melphalan (100 mg/m²) followed by stem cell transplantation in newly diagnosed multiple myeloma patients. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00205764?utm_source=openai))

- **NCT00002568**: A phase III trial that assessed single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma patients. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26990892/?utm_source=openai))

While these studies provide insights into tandem melphalan therapies, they do not offer a direct comparison to the CRd regimen. For the most current and comprehensive information, consulting clinical trial registries or recent medical literature is recommended. ",NCT00205764,False,
"Find/search the clinical trial id that best describes the efficacy of BEP compared to T-BEP when used to treat Testicular cancer.
Output it in the format NCT<Number>",NCT00003643,"The clinical trial that evaluated the efficacy of BEP (bleomycin, etoposide, and cisplatin) compared to T-BEP (paclitaxel–bleomycin, etoposide, and cisplatin) in treating intermediate-prognosis germ-cell cancer is identified as EORTC 30983. This study was conducted by the European Organisation for Research and Treatment of Cancer (EORTC) and does not have a corresponding NCT number. ([ascopubs.org](https://ascopubs.org/doi/10.1200/JCO.2011.37.0171?utm_source=openai)) ",,False,
"Find/search the clinical trial id that best describes the efficacy of PGC compared to Cisplatin and Gemcitabine (GC) when used to treat Urothelial carcinoma.
Output it in the format NCT<Number>",NCT00022191,"The clinical trial that best describes the efficacy of paclitaxel, gemcitabine, and cisplatin (PGC) compared to gemcitabine and cisplatin (GC) in treating urothelial carcinoma is registered under the identifier NCT00014214. This randomized phase III study, known as EORTC Intergroup Study 30987, evaluated the overall survival and response rates between the two treatment regimens. The results indicated an improved response rate with PGC (57%) compared to GC (46%), though the difference in overall survival was not statistically significant. ([onlinelibrary.wiley.com](https://onlinelibrary.wiley.com/doi/full/10.1100/2011/590175?utm_source=openai)) ",NCT00014214,False,
"Find/search the clinical trial id that best describes the efficacy of FULV compared to FOLFIRI when used to treat Colorectal cancer.
Output it in the format NCT<Number>",NCT00004885,"I couldn't locate a clinical trial that directly compares FULV (fluorouracil and leucovorin) to FOLFIRI (fluorouracil, leucovorin, and irinotecan) in the treatment of colorectal cancer. However, a relevant study is NCT02935764, which compared FOLFIRI to single-agent irinotecan in patients with metastatic colorectal cancer who had failed first-line XELOX/FOLFOX regimens. The study found no significant difference in progression-free survival, overall survival, or objective response rate between the two groups, but noted higher toxicity in the FOLFIRI group. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35069808/?utm_source=openai)) ",NCT02935764,False,
"Find/search the clinical trial id that best describes the efficacy of MOPP-ABV, then Radiation therapy compared to Radiation therapy when used to treat Classical Hodgkin lymphoma.
Output it in the format NCT<Number>",NCT00379041,The clinical trial that best describes the efficacy of MOPP-ABV chemotherapy followed by radiation therapy compared to radiation therapy alone in treating Classical Hodgkin lymphoma is identified by the ClinicalTrials.gov identifier NCT00002415. ,NCT00002415,False,
"Find/search the clinical trial id that best describes the efficacy of Radiation therapy compared to Observation when used to treat Classical Hodgkin lymphoma.
Output it in the format NCT<Number>",NCT00005584,"I couldn't locate a specific clinical trial with an identifier (NCT number) that directly compares radiation therapy to observation in the treatment of classical Hodgkin lymphoma. However, several studies have investigated the role of radiation therapy in managing this condition:

- **Early-Stage Hodgkin Lymphoma**: A study analyzing data from the National Cancer Database found that the use of radiation therapy was associated with improved overall survival in patients with stage I/II Hodgkin lymphoma. The 5-year overall survival rate was 94.5% for those receiving radiation therapy, compared to 88.9% for those who did not. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26279323/?utm_source=openai))

- **Stage IV Hodgkin Lymphoma**: Research utilizing the Surveillance, Epidemiology, and End Results (SEER) database indicated that radiation therapy was linked to better survival outcomes in patients with stage IV classical Hodgkin lymphoma. The study suggested that incorporating radiation therapy could improve overall and cancer-specific survival rates. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7537794/?utm_source=openai))

- **Trends in Treatment**: An analysis of treatment patterns from 2004 to 2018 showed a decline in the use of combined modality therapy (chemotherapy plus radiation therapy) for early-stage classical Hodgkin lymphoma. Despite this trend, the study found that patients receiving combined modality therapy had better overall survival compared to those receiving chemotherapy alone. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35904407/?utm_source=openai))

While these studies highlight the potential benefits of radiation therapy in treating classical Hodgkin lymphoma, they do not provide a direct comparison between radiation therapy and observation alone. For the most current and specific clinical trial information, consulting the [ClinicalTrials.gov](https://clinicaltrials.gov/) database or discussing with a healthcare professional is recommended. ",,False,
"Find/search the clinical trial id that best describes the efficacy of ADE (standard-dose Ara-C) compared to ADE (high-dose Ara-C) when used to treat Acute myeloid leukemia.
Output it in the format NCT<Number>",NCT00004128,"The clinical trial that best describes the efficacy of ADE (standard-dose Ara-C) compared to ADE (high-dose Ara-C) in treating acute myeloid leukemia is identified by the ClinicalTrials.gov identifier NCT00004128. This trial, known as the EORTC-GIMEMA AML-12 study, evaluated the impact of high-dose versus standard-dose cytarabine in induction treatment for adult patients with acute myeloid leukemia. ([ascopubs.org](https://ascopubs.org/doi/full/10.1200/JCO.2013.51.8571?utm_source=openai)) ",NCT00004128,True,
"Find/search the clinical trial id that best describes the efficacy of Camrelizumab monotherapy compared to Irinotecan monotherapy when used to treat Esophageal squamous cell carcinoma.
Output it in the format NCT<Number>",NCT03099382,"The clinical trial that best describes the efficacy of camrelizumab monotherapy compared to chemotherapy (including irinotecan) in treating esophageal squamous cell carcinoma is identified by the ClinicalTrials.gov identifier NCT03155425. This phase III study, known as the ESCORT trial, evaluated camrelizumab versus investigator's choice of chemotherapy (docetaxel or irinotecan) as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma. ([frontiersin.org](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.732912/full?utm_source=openai)) ",NCT03155425,False,
"Find/search the clinical trial id that best describes the efficacy of Erlotinib monotherapy compared to Cisplatin and Docetaxel (DC) when used to treat Non-small cell lung cancer (Metastatic).
Output it in the format NCT<Number>",NCT00446225,The clinical trial that best describes the efficacy of erlotinib monotherapy compared to docetaxel in treating metastatic non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT00637910. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23883922/?utm_source=openai)) ,NCT00637910,False,
"Find/search the clinical trial id that best describes the efficacy of Gemcitabine monotherapy compared to Cisplatin and Fluorouracil (CF), then Gemcitabine monotherapy when used to treat Pancreatic cancer.
Output it in the format NCT<Number>",NCT00416507,"The clinical trial that best describes the efficacy of gemcitabine monotherapy compared to a combination regimen including cisplatin and fluorouracil in the treatment of pancreatic cancer is identified by the ClinicalTrials.gov identifier NCT00813696. ([ascopubs.org](https://ascopubs.org/doi/10.1200/JCO.2009.25.4433?utm_source=openai))

This randomized Phase III trial, known as the GIP-1 study, compared gemcitabine alone to gemcitabine plus cisplatin as first-line treatment for patients with advanced pancreatic cancer. The study concluded that the addition of weekly cisplatin to gemcitabine did not demonstrate any improvement in overall survival compared to gemcitabine monotherapy.

Another relevant study is identified by the ClinicalTrials.gov identifier NCT00154102. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15925814/?utm_source=openai)) This randomized controlled multicenter Phase III trial compared gemcitabine monotherapy to a combination regimen of cisplatin, epirubicin, fluorouracil, and gemcitabine (PEFG) in patients with advanced pancreatic cancer. The study found that the PEFG regimen could be considered for treatment of advanced pancreatic adenocarcinoma, as it showed improved progression-free survival and overall survival compared to gemcitabine alone.

Therefore, the clinical trial identifiers NCT00813696 and NCT00154102 are pertinent to studies evaluating the efficacy of gemcitabine monotherapy versus combination therapies including cisplatin and fluorouracil in pancreatic cancer treatment. ",NCT00813696,False,
"Find/search the clinical trial id that best describes the efficacy of Cyclosporine and Mycophenolate mofetil compared to Cyclosporine, Mycophenolate mofetil, Sirolimus when used to treat Graft versus host disease.
Output it in the format NCT<Number>",NCT01231412,"The clinical trial that best describes the efficacy of Cyclosporine and Mycophenolate Mofetil compared to Cyclosporine, Mycophenolate Mofetil, and Sirolimus in treating Graft-versus-Host Disease is registered under the identifier NCT01251575. ([ashpublications.org](https://ashpublications.org/blood/article/136/13/1499/461231/Sirolimus-with-CSP-and-MMF-as-GVHD-prophylaxis-for?utm_source=openai)) ",NCT01251575,False,
"Find/search the clinical trial id that best describes the efficacy of Fludarabine and TBI compared to Low-dose TBI when used to treat Allogeneic HSCT.
Output it in the format NCT<Number>",NCT00075478,"The clinical trial that best describes the efficacy of Fludarabine and Total Body Irradiation (TBI) compared to low-dose TBI in the context of allogeneic hematopoietic stem cell transplantation (HSCT) is registered under the identifier NCT01366612. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01366612?utm_source=openai))

This Phase III study, conducted at the John Theurer Cancer Center at Hackensack University Medical Center, enrolled 80 subjects to compare two conditioning regimens:

- Fludarabine and Busulfan
- Fludarabine, Busulfan, and low-dose TBI

The primary objective was to assess the relapse rate and transplant-related toxicity up to one year post-transplantation.

Additionally, a related Phase III randomized trial demonstrated that adding Fludarabine to a 2-Gy TBI nonmyeloablative regimen resulted in superior outcomes compared to 2-Gy TBI alone. The study found that the combination led to higher overall survival, lower relapse rates, and improved progression-free survival. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23769990/?utm_source=openai)) ",NCT01366612,False,
"Find/search the clinical trial id that best describes the efficacy of PCDE compared to Cisplatin and Etoposide (EP) when used to treat Small cell lung cancer.
Output it in the format NCT<Number>",NCT00003606,"The clinical trial that best describes the efficacy of the PCDE regimen compared to the EP regimen in treating extensive small-cell lung cancer is identified by the ClinicalTrials.gov identifier NCT00658580. ([frontiersin.org](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2017.00217/full?utm_source=openai))

In this phase III randomized study, patients were assigned to receive either the PCDE regimen (etoposide and cisplatin plus cyclophosphamide and 4'-epidoxorubicin) or the EP regimen (etoposide plus cisplatin). The results indicated that the PCDE regimen yielded higher response rates and better survival rates compared to the EP regimen, without adversely affecting the quality of life during chemotherapy. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11181777/?utm_source=openai)) ",NCT00658580,False,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide monotherapy compared to Carfilzomib and Lenalidomide (KR) when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT02203643,"The clinical trial that best describes the efficacy of lenalidomide monotherapy compared to carfilzomib and lenalidomide (KR) in treating multiple myeloma is identified by the ClinicalTrials.gov identifier NCT01080391. This phase 3 study, known as the ASPIRE trial, evaluated the combination of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma. The results demonstrated a significant improvement in progression-free survival for the KRd regimen compared to Rd. ([nejm.org](https://www.nejm.org/doi/full/10.1056/nejmoa1411321?utm_source=openai)) ",NCT01080391,False,
"Find/search the clinical trial id that best describes the efficacy of Venetoclax and Obinutuzumab compared to Bendamustine and Rituximab (BR) when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT02950051,"The clinical trial that best describes the efficacy of Venetoclax and Obinutuzumab compared to Bendamustine and Rituximab in treating Chronic Lymphocytic Leukemia is identified by the ClinicalTrials.gov identifier NCT02242942. This phase 3, open-label trial evaluated various treatment regimens, including Venetoclax combined with Obinutuzumab, and compared them to chemoimmunotherapy options such as Bendamustine and Rituximab. ([nejm.org](https://www.nejm.org/doi/10.1056/NEJMoa2213093?utm_source=openai)) ",NCT02242942,False,
"Find/search the clinical trial id that best describes the efficacy of Dexamethasone monotherapy compared to Thalidomide and Dexamethasone (TD) when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01296503,"The clinical trial that best describes the efficacy of dexamethasone monotherapy compared to thalidomide and dexamethasone (TD) in treating multiple myeloma is identified by the ClinicalTrials.gov identifier NCT00033332. ([clinicaltrials.stanford.edu](https://clinicaltrials.stanford.edu/trials/d/NCT00033332.html?utm_source=openai))

This randomized phase III trial evaluated the effectiveness of dexamethasone with or without thalidomide in patients with newly diagnosed multiple myeloma. The study aimed to determine whether the combination of thalidomide and dexamethasone was more effective than dexamethasone alone in treating the disease. ",NCT00033332,False,
"Find/search the clinical trial id that best describes the efficacy of Observation compared to Lenalidomide monotherapy when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT01556776,"I couldn't locate a clinical trial that directly compares observation to lenalidomide monotherapy in the treatment of chronic lymphocytic leukemia (CLL). However, there is a relevant study, identified as NCT00910910, which evaluates the efficacy of lenalidomide in patients with previously untreated CLL. This phase II trial investigates lenalidomide's effectiveness and safety in this patient population.

For more detailed information, you can refer to the study's record on ClinicalTrials.gov: [NCT00910910](https://clinicaltrials.gov/ct2/show/NCT00910910). ",NCT00910910,False,
"Find/search the clinical trial id that best describes the efficacy of FAC compared to FAC-T when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00129389,"I couldn't locate a specific clinical trial comparing the efficacy of FAC (5-Fluorouracil, Doxorubicin, and Cyclophosphamide) versus FAC-T (FAC plus Taxane) in the treatment of breast cancer. However, the addition of taxanes to chemotherapy regimens like FAC has been extensively studied and is generally associated with improved outcomes in breast cancer treatment.

For the most accurate and up-to-date information, I recommend consulting the [ClinicalTrials.gov](https://clinicaltrials.gov/) database or discussing with a healthcare professional. ",,False,
"Find/search the clinical trial id that best describes the efficacy of ET-X compared to EC-D when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00129935,"I couldn't locate a clinical trial directly comparing the efficacy of ET-X (Epirubicin and Tamoxifen) to EC-D (Epirubicin, Cyclophosphamide, and Docetaxel) in the treatment of breast cancer. However, there are studies evaluating the efficacy of these regimens individually.

For instance, a study found that combining Epirubicin with Tamoxifen increased survival in node-positive postmenopausal women with hormone receptor-positive breast tumors. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Epirubicin?utm_source=openai))

Additionally, the KATHERINE trial (NCT01772472) assessed the efficacy of Trastuzumab Emtansine in HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Trastuzumab_emtansine?utm_source=openai))

While these studies provide insights into the efficacy of these treatments, a direct comparison between ET-X and EC-D in a clinical trial appears to be lacking. ",NCT01772472,False,
"Find/search the clinical trial id that best describes the efficacy of EC-TH (Docetaxel) compared to EC-TL (Docetaxel) when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00841828,"I couldn't locate a specific clinical trial comparing the efficacy of EC-TH (Epirubicin, Cyclophosphamide, Docetaxel, and Trastuzumab) versus EC-TL (Epirubicin, Cyclophosphamide, Docetaxel, and Lapatinib) in the treatment of breast cancer. However, there are several clinical trials that have investigated the efficacy of these regimens individually or in combination with other therapies. For instance:

- **NCT00553358**: This study evaluated the efficacy of EC-TH in patients with HER2-positive breast cancer.

- **NCT00374322**: This trial assessed the combination of EC-TL in treating HER2-positive breast cancer.

While these trials provide valuable insights into the effectiveness of each regimen, a direct head-to-head comparison between EC-TH and EC-TL appears to be lacking. ",NCT00553358,False,
"Find/search the clinical trial id that best describes the efficacy of TAC (Docetaxel) compared to FAC when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00121992,"The clinical trial that best describes the efficacy of TAC (Docetaxel) compared to FAC in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT00003088. This study evaluated the effectiveness of the TAC regimen (Docetaxel, Doxorubicin, and Cyclophosphamide) versus the FAC regimen (Fluorouracil, Doxorubicin, and Cyclophosphamide) in patients with operable breast cancer. ",NCT00003088,False,
"Find/search the clinical trial id that best describes the efficacy of FEC-P compared to FEC when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00129922,"The clinical trial that best describes the efficacy of FEC-P (Fluorouracil, Epirubicin, and Cyclophosphamide followed by Paclitaxel) compared to FEC (Fluorouracil, Epirubicin, and Cyclophosphamide) in treating breast cancer is registered under the identifier NCT00129922. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00129922?utm_source=openai)) ",NCT00129922,True,
"Find/search the clinical trial id that best describes the efficacy of Ibrutinib monotherapy compared to Ibrutinib and Ublituximab when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT02301156,The clinical trial that best describes the efficacy of ibrutinib monotherapy compared to the combination of ibrutinib and ublituximab in treating chronic lymphocytic leukemia is identified by the ClinicalTrials.gov identifier NCT02301156. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT02301156?utm_source=openai)) ,NCT02301156,True,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide monotherapy compared to Erythropoetin beta and Lenalidomide when used to treat Myelodysplastic syndrome.
Output it in the format NCT<Number>",NCT01718379,The clinical trial that best describes the efficacy of lenalidomide monotherapy compared to lenalidomide combined with erythropoietin alfa in treating myelodysplastic syndromes is registered under the identifier NCT02048813. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33439748/?utm_source=openai)) ,NCT02048813,False,
"Find/search the clinical trial id that best describes the efficacy of Methotrexate monotherapy compared to Dactinomycin monotherapy when used to treat Gestational trophoblastic neoplasia.
Output it in the format NCT<Number>",NCT00003702,The clinical trial that best describes the efficacy of methotrexate monotherapy compared to dactinomycin monotherapy in treating gestational trophoblastic neoplasia is identified by the ClinicalTrials.gov identifier NCT01535053. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32460997/?utm_source=openai)) ,NCT01535053,False,
"Find/search the clinical trial id that best describes the efficacy of Ifosfamide and Paclitaxel compared to Ifosfamide monotherapy when used to treat Endometrial cancer.
Output it in the format NCT<Number>",NCT00003128,The clinical trial that best describes the efficacy of Ifosfamide and Paclitaxel compared to Ifosfamide monotherapy in treating endometrial cancer is identified by the ClinicalTrials.gov identifier NCT00003128. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00003128?utm_source=openai)) ,NCT00003128,True,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin, Doxorubicin, Paclitaxel compared to Cisplatin and Doxorubicin when used to treat Endometrial cancer.
Output it in the format NCT<Number>",NCT00003691,"The clinical trial that best describes the efficacy of Cisplatin, Doxorubicin, and Paclitaxel compared to Cisplatin and Doxorubicin in treating endometrial cancer is identified by the ClinicalTrials.gov identifier NCT00006360. This Phase III trial, conducted by the Gynecologic Oncology Group (GOG), evaluated whether adding Paclitaxel to a regimen of Doxorubicin and Cisplatin, along with volume-directed radiation therapy, improved overall survival and recurrence-free survival in patients with advanced-stage endometrial cancer. The study concluded that the addition of Paclitaxel did not significantly enhance survival outcomes compared to the regimen without it. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31053405/?utm_source=openai)) ",NCT00006360,False,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin and Paclitaxel compared to Cisplatin and Gemcitabine (GC) when used to treat Cervical cancer.
Output it in the format NCT<Number>",NCT00064077,"I couldn't find a specific clinical trial comparing the efficacy of Cisplatin and Paclitaxel versus Cisplatin and Gemcitabine in treating cervical cancer. However, studies have established the combination of a platinum agent (like Cisplatin) and Paclitaxel as a standard treatment for recurrent cervical cancer. Notably, Dr. Bradley J. Monk contributed to this standard by defining the systemic therapy approach in 2009. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Bradley_J._Monk?utm_source=openai))

For more detailed information or specific clinical trials, consulting the ClinicalTrials.gov database or discussing with a healthcare professional is recommended. ",,False,
"Find/search the clinical trial id that best describes the efficacy of Paclitaxel monotherapy compared to Olaparib and Paclitaxel when used to treat Gastric cancer.
Output it in the format NCT<Number>",NCT01924533,"The clinical trial that best describes the efficacy of paclitaxel monotherapy compared to the combination of olaparib and paclitaxel in treating gastric cancer is registered under the identifier NCT01924533. This phase III study, known as the GOLD trial, evaluated the combination of olaparib and paclitaxel versus placebo and paclitaxel in patients with advanced gastric cancer who had progressed following first-line therapy. The results indicated that the combination did not significantly improve overall survival compared to paclitaxel alone. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29103871/?utm_source=openai)) ",NCT01924533,True,
"Find/search the clinical trial id that best describes the efficacy of ABVD compared to eBEACOPP-BEACOPP when used to treat Classical Hodgkin lymphoma.
Output it in the format NCT<Number>",NCT01251107,"The clinical trial that best describes the efficacy of ABVD compared to BEACOPP in treating Classical Hodgkin lymphoma is registered under the identifier NCT01251107. This trial, conducted by Fondazione Michelangelo, compared the two regimens in patients with advanced-stage Hodgkin's lymphoma. The results indicated that while BEACOPP provided better initial tumor control, the long-term clinical outcomes did not differ significantly between the two treatments. ([nejm.org](https://www.nejm.org/doi/full/10.1056/nejmoa1100340?utm_source=openai)) ",NCT01251107,True,
"Find/search the clinical trial id that best describes the efficacy of EC-D and Bevacizumab compared to EC-D when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00567554,"The clinical trial that best describes the efficacy of EC-D (Epirubicin, Cyclophosphamide, and Docetaxel) combined with Bevacizumab compared to EC-D alone in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT00433511. ([ascopubs.org](https://ascopubs.org/doi/10.1200/JCO.2018.79.2028?utm_source=openai)) ",NCT00433511,False,
"Find/search the clinical trial id that best describes the efficacy of Letrozole and OFS compared to Tamoxifen and OFS when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00412022,"The clinical trial that best describes the efficacy of Letrozole and ovarian function suppression (OFS) compared to Tamoxifen and OFS in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT00066703. This trial, known as the Suppression of Ovarian Function Trial (SOFT), evaluated the role of OFS combined with either Tamoxifen or an aromatase inhibitor like Letrozole in premenopausal women with hormone receptor-positive breast cancer. ",NCT00066703,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Epirubicin compared to E-D when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00424606,"The clinical trial that best describes the efficacy of Docetaxel and Epirubicin compared to Epirubicin alone in treating breast cancer is the DEVA trial, registered under ClinicalTrials.gov identifier NCT00003435. This randomized phase III trial evaluated the efficacy and toxicity of incorporating docetaxel after epirubicin to create a sequential anthracycline-taxane regimen in early breast cancer. ([ascopubs.org](https://ascopubs.org/doi/full/10.1200/JCO.2010.32.7254?utm_source=openai)) ",NCT00003435,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Vinorelbine monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT00441922,"The clinical trial that best describes the efficacy of docetaxel monotherapy compared to vinorelbine monotherapy in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT00190502. This phase III study, conducted by the West Japan Thoracic Oncology Group (WJTOG 9904), evaluated the efficacy and safety of docetaxel versus vinorelbine in elderly patients with advanced non-small-cell lung cancer. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16877734/?utm_source=openai)) ",NCT00190502,False,
"Find/search the clinical trial id that best describes the efficacy of R-DHAP/R-VIM compared to DHAP/VIM when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT00012051,"I couldn't locate a specific clinical trial comparing the efficacy of R-DHAP/R-VIM to DHAP/VIM in treating Diffuse Large B-Cell Lymphoma (DLBCL). However, a related study, identified as NCT00137995, evaluated the effectiveness of R-ICE (Rituximab, Ifosfamide, Carboplatin, and Etoposide) versus R-DHAP (Rituximab, Dexamethasone, Cytarabine, and Cisplatin) in patients with relapsed or refractory DLBCL. This trial aimed to determine which regimen was more effective as a salvage therapy prior to autologous stem cell transplantation.

For more detailed information on this study, you can visit the ClinicalTrials.gov page:

While this trial doesn't directly compare R-DHAP/R-VIM to DHAP/VIM, it may provide insights into the efficacy of similar regimens in the treatment of DLBCL. ",NCT00137995,False,
"Find/search the clinical trial id that best describes the efficacy of Busulfan and Melphalan compared to Carboplatin, Etoposide, Melphalan, then auto HSCT when used to treat Neuroblastoma.
Output it in the format NCT<Number>",NCT01704716,"The clinical trial that best describes the efficacy of Busulfan and Melphalan compared to Carboplatin, Etoposide, and Melphalan, followed by autologous hematopoietic stem cell transplantation (HSCT) in treating neuroblastoma, is registered under the identifier NCT01704716. This international, randomized, multi-arm, open-label, phase 3 trial, known as HR-NBL1/SIOPEN, evaluated these high-dose chemotherapy regimens in patients with high-risk neuroblastoma. ([academia.edu](https://www.academia.edu/84675906/Busulfan_and_melphalan_versus_carboplatin_etoposide_and_melphalan_as_high_dose_chemotherapy_for_high_risk_neuroblastoma_HR_NBL1_SIOPEN_an_international_randomised_multi_arm_open_label_phase_3_trial?utm_source=openai)) ",NCT01704716,True,
"Find/search the clinical trial id that best describes the efficacy of Melphalan monotherapy compared to Melphalan and Dexamethasone when used to treat Light-chain (AL) amyloidosis.
Output it in the format NCT<Number>",NCT00344526,The clinical trial that best describes the efficacy of Melphalan monotherapy compared to Melphalan and Dexamethasone in treating Light-chain (AL) amyloidosis is identified by the ClinicalTrials.gov identifier NCT00223565. ,NCT00223565,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin monotherapy compared to Carboplatin and Paclitaxel (CP)|Cisplatin and Paclitaxel when used to treat Ovarian cancer.
Output it in the format NCT<Number>",NCT00002894,"The clinical trial that best describes the efficacy of carboplatin monotherapy compared to carboplatin plus paclitaxel in treating ovarian cancer is registered under the identifier NCT02001272. This randomized clinical trial evaluated the feasibility, efficacy, and safety of single-agent carboplatin versus carboplatin combined with paclitaxel in vulnerable older adult women with ovarian cancer. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8063137/?utm_source=openai)) ",NCT02001272,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Lenalidomide monotherapy when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00430365,"The clinical trial that best describes the efficacy of lenalidomide monotherapy compared to placebo in treating multiple myeloma is identified by the ClinicalTrials.gov identifier NCT00114101. This Phase III study, known as CALGB 100104, investigated whether maintenance therapy with lenalidomide following a single autologous stem cell transplant could prolong the time to disease progression in patients with multiple myeloma. ([nejm.org](https://www.nejm.org/doi/full/10.1056/nejmoa1114083?utm_source=openai)) ",NCT00114101,False,
"Find/search the clinical trial id that best describes the efficacy of VDC compared to VTD when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01971658,"The clinical trial that best describes the efficacy of bortezomib, thalidomide, and dexamethasone (VTD) compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) in treating multiple myeloma is registered under the identifier NCT01564537. This study, known as the IFM2013-04 trial, was conducted by the Intergroupe Francophone du Myélome. It demonstrated that VTD was superior to VCD as induction therapy prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27002117/?utm_source=openai)) ",NCT01564537,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin, Pemetrexed, Atezolizumab compared to Carboplatin and Pemetrexed|Cisplatin and Pemetrexed when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT02657434,The clinical trial that evaluates the efficacy of Atezolizumab in combination with Carboplatin or Cisplatin plus Pemetrexed compared to Carboplatin or Cisplatin plus Pemetrexed alone in treating chemotherapy-naive patients with Stage IV non-squamous non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT02657434. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT02657434/?utm_source=openai)) ,NCT02657434,True,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Pemetrexed compared to Pemetrexed monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT01836575,The clinical trial that best describes the efficacy of Carboplatin and Pemetrexed compared to Pemetrexed monotherapy in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT00786331. ([ascopubs.org](https://ascopubs.org/doi/full/10.1200/JCO.2012.43.6758?utm_source=openai)) ,NCT00786331,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Gefitinib monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT00478049,"The clinical trial that best describes the efficacy of docetaxel monotherapy compared to gefitinib monotherapy in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT00076388. This Phase III trial, known as the INTEREST study, compared gefitinib (250 mg/day) with docetaxel (75 mg/m² intravenously every 3 weeks) in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy. The study concluded that gefitinib was non-inferior to docetaxel in terms of overall survival, suggesting that gefitinib is a valid treatment option for pretreated patients with advanced non-small-cell lung cancer. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/19027483/?utm_source=openai)) ",NCT00076388,False,
"Find/search the clinical trial id that best describes the efficacy of Prednisone monotherapy compared to Dexamethasone monotherapy when used to treat Immune thrombocytopenia.
Output it in the format NCT<Number>",NCT01356511,The clinical trial that best describes the efficacy of prednisone monotherapy compared to dexamethasone monotherapy in treating immune thrombocytopenia is registered under the identifier NCT00657410. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38231017/?utm_source=openai)) ,NCT00657410,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Docetaxel and Ramucirumab when used to treat Urothelial carcinoma.
Output it in the format NCT<Number>",NCT01282463,The clinical trial that best describes the efficacy of docetaxel monotherapy compared to docetaxel combined with ramucirumab in treating urothelial carcinoma is registered under the identifier NCT01282463. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26926681/?utm_source=openai)) ,NCT01282463,True,
"Find/search the clinical trial id that best describes the efficacy of Pemetrexed monotherapy compared to Best supportive care when used to treat Malignant pleural mesothelioma.
Output it in the format NCT<Number>",NCT00190762,The clinical trial that best describes the efficacy of pemetrexed monotherapy compared to best supportive care in treating malignant pleural mesothelioma is identified by the ClinicalTrials.gov identifier NCT00190762. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00190762?utm_source=openai)) ,NCT00190762,True,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Etoposide (CE) compared to Carboplatin and Pemetrexed when used to treat Small cell lung cancer.
Output it in the format NCT<Number>",NCT00363415,The clinical trial that best describes the efficacy of Carboplatin and Etoposide (CE) compared to Carboplatin and Pemetrexed in treating extensive-stage small cell lung cancer is registered under the identifier NCT00363415. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00363415?utm_source=openai)) ,NCT00363415,True,
"Find/search the clinical trial id that best describes the efficacy of Gefitinib and Pemetrexed compared to Gefitinib monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT01469000,The clinical trial that best describes the efficacy of Gefitinib combined with Pemetrexed compared to Gefitinib monotherapy in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT01555186. This randomized phase II trial evaluated the combination of Gefitinib and Pemetrexed as first-line therapy in patients with advanced nonsquamous non–small-cell lung cancer harboring activating epidermal growth factor receptor mutations. ([ascopubs.org](https://ascopubs.org/doi/full/10.1200/JCO.2016.66.9218?utm_source=openai)) ,NCT01555186,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Pemetrexed compared to Carboplatin, Pemetrexed, Pembrolizumab when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT02039674,"The clinical trial that best describes the efficacy of Carboplatin and Pemetrexed compared to Carboplatin, Pemetrexed, and Pembrolizumab in treating non-squamous non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT02039674. This trial, known as KEYNOTE-021, evaluated the combination of pembrolizumab with carboplatin and pemetrexed versus carboplatin and pemetrexed alone in patients with advanced non-squamous non-small cell lung cancer. ([sciencedirect.com](https://www.sciencedirect.com/science/article/abs/pii/S1470204516304983?utm_source=openai)) ",NCT02039674,True,
"Find/search the clinical trial id that best describes the efficacy of Pembrolizumab monotherapy compared to Carboplatin and Paclitaxel (CP)|Carboplatin and Pemetrexed when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT03850444,"The clinical trial that best describes the efficacy of pembrolizumab monotherapy compared to chemotherapy regimens, including carboplatin and paclitaxel or carboplatin and pemetrexed, in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT02142738. This trial, known as KEYNOTE-024, evaluated pembrolizumab monotherapy versus platinum-based chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) expressing PD-L1 on at least 50% of tumor cells. The results demonstrated that pembrolizumab was associated with significantly longer progression-free and overall survival compared to chemotherapy. ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa1606774?utm_source=openai)) ",NCT02142738,False,
"Find/search the clinical trial id that best describes the efficacy of Pembrolizumab monotherapy compared to Paclitaxel monotherapy when used to treat Gastric cancer.
Output it in the format NCT<Number>",NCT03019588,"The clinical trial that best describes the efficacy of pembrolizumab monotherapy compared to paclitaxel monotherapy in treating gastric cancer is identified by the ClinicalTrials.gov identifier NCT02370498. This trial, known as KEYNOTE-061, was a randomized, open-label, phase 3 study evaluating these treatments in patients with previously treated, advanced gastric or gastroesophageal junction cancer. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29880231/?utm_source=openai)) ",NCT02370498,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin, nab-Paclitaxel, Pembrolizumab compared to Carboplatin and Paclitaxel (CP)|Carboplatin and nab-Paclitaxel when used to treat Non-small cell lung cancer squamous.
Output it in the format NCT<Number>",NCT03875092,"The clinical trial that best describes the efficacy of Carboplatin, nab-Paclitaxel, and Pembrolizumab compared to Carboplatin and Paclitaxel or Carboplatin and nab-Paclitaxel in treating non-small cell lung cancer (NSCLC) squamous is identified by the ClinicalTrials.gov identifier NCT02775435. ([nejm.org](https://www.nejm.org/doi/10.1056/NEJMoa1810865?utm_source=openai)) ",NCT02775435,False,
"Find/search the clinical trial id that best describes the efficacy of Capecitabine and Cisplatin (CX) compared to Capecitabine and Cisplatin (CX) and Pembrolizumab|Cisplatin and Fluorouracil (CF) and Pembrolizumab when used to treat Gastric cancer.
Output it in the format NCT<Number>",NCT03221426,"The clinical trial that best describes the efficacy of Capecitabine and Cisplatin (CX) compared to Capecitabine and Cisplatin (CX) combined with Pembrolizumab, as well as Cisplatin and Fluorouracil (CF) combined with Pembrolizumab, in the treatment of gastric cancer is identified by the ClinicalTrials.gov identifier NCT02494583. ([mycancergenome.org](https://www.mycancergenome.org/content/clinical_trials/NCT02494583/?utm_source=openai)) ",NCT02494583,False,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin and Pemetrexed compared to Cisplatin, Pemetrexed, Pembrolizumab when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT03425643,"The clinical trial that best describes the efficacy of Cisplatin and Pemetrexed compared to Cisplatin, Pemetrexed, and Pembrolizumab in treating nonsquamous non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT02578680. This Phase 3 study, known as KEYNOTE-189, evaluated the combination of pembrolizumab with pemetrexed and platinum chemotherapy versus chemotherapy alone in patients with metastatic nonsquamous non-small cell lung cancer. ([ctv.veeva.com](https://ctv.veeva.com/study/study-of-pemetrexed-platinum-chemotherapy-with-or-without-pembrolizumab-mk-3475-in-participants-wi?utm_source=openai)) ",NCT02578680,False,
"Find/search the clinical trial id that best describes the efficacy of Dara-Vd compared to Bortezomib and Dexamethasone (Vd) when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT03234972,"The clinical trial that best describes the efficacy of Daratumumab combined with Bortezomib and Dexamethasone (Dara-Vd) compared to Bortezomib and Dexamethasone (Vd) in treating multiple myeloma is identified by the ClinicalTrials.gov number NCT02136134. This Phase 3 study, known as the CASTOR trial, evaluated the addition of Daratumumab to the Vd regimen in patients with relapsed or refractory multiple myeloma. ([themyelomaclinicaltrials.com](https://www.themyelomaclinicaltrials.com/single-post/castor?utm_source=openai)) ",NCT02136134,False,
"Find/search the clinical trial id that best describes the efficacy of Ipatasertib and Paclitaxel compared to Paclitaxel monotherapy when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT02162719,"The clinical trial that evaluated the efficacy of ipatasertib combined with paclitaxel compared to paclitaxel monotherapy in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT02162719. This study, known as the LOTUS trial, was a randomized, double-blind, placebo-controlled phase 2 trial focusing on patients with metastatic triple-negative breast cancer. ([themednet.org](https://www.themednet.org/publications/ipatasertib-plus-paclitaxel-versus-placebo-plus-paclitaxel-as-first-line-therapy-for-metastatic-triple-negative-breast-cancer-lotus-a-multicentre-randomised-double-blind-placebo-controlled-phase-2-trial?utm_source=openai)) ",NCT02162719,True,
"Find/search the clinical trial id that best describes the efficacy of Nintedanib and Pemetrexed compared to Pemetrexed monotherapy when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT00806819,The clinical trial that best describes the efficacy of nintedanib combined with pemetrexed compared to pemetrexed monotherapy in treating non-squamous non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT00806819. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00806819?utm_source=openai)) ,NCT00806819,True,
"Find/search the clinical trial id that best describes the efficacy of Methotrexate monotherapy compared to Afatinib monotherapy when used to treat Head and neck cancer.
Output it in the format NCT<Number>",NCT01345682,The clinical trial that best describes the efficacy of methotrexate monotherapy compared to afatinib monotherapy in treating head and neck cancer is identified by the ClinicalTrials.gov identifier NCT01345682. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25892145/?utm_source=openai)) ,NCT01345682,True,
"Find/search the clinical trial id that best describes the efficacy of Methotrexate monotherapy compared to Afatinib monotherapy when used to treat Head and neck cancer.
Output it in the format NCT<Number>",NCT01856478,"The clinical trial that best describes the efficacy of Methotrexate monotherapy compared to Afatinib monotherapy in treating head and neck cancer is the LUX-Head & Neck 1 study. This Phase III trial evaluated Afatinib versus Methotrexate as second-line treatment for patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. The primary efficacy results were presented at the European Society for Medical Oncology (ESMO) 2014 Congress. ([zh.wikipedia.org](https://zh.wikipedia.org/wiki/%E9%98%BF%E6%B3%95%E6%9B%BF%E5%B0%BC?utm_source=openai))

The ClinicalTrials.gov identifier for this study is NCT01345682. ",NCT01345682,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Pemetrexed compared to Carboplatin, Pemetrexed, Amivantamab when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT04988295,"The clinical trial that best describes the efficacy of Carboplatin and Pemetrexed compared to Carboplatin, Pemetrexed, and Amivantamab in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT04538664. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT04538664?utm_source=openai)) ",NCT04538664,False,
"Find/search the clinical trial id that best describes the efficacy of Azacitidine monotherapy compared to Decitabine monotherapy when used to treat Myelodysplastic syndrome.
Output it in the format NCT<Number>",NCT01720225,The clinical trial that directly compares the efficacy of azacitidine monotherapy to decitabine monotherapy in treating myelodysplastic syndrome is registered under the identifier NCT01409070. ([trial.medpath.com](https://trial.medpath.com/clinical-trial/3c108de762bc5d51/nct01409070-comparison-azacitidine-decitabine-myelodysplastic-syndrome?utm_source=openai)) ,NCT01409070,False,
"Find/search the clinical trial id that best describes the efficacy of R-Hyper-CVAD/R-MA compared to R-CHOP when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT00290498,"I couldn't locate a specific clinical trial comparing the efficacy of R-Hyper-CVAD/R-MA to R-CHOP in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). However, studies have evaluated other regimens against R-CHOP. For instance, the POLARIX trial (NCT03274492) assessed the combination of polatuzumab vedotin with R-CHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) compared to standard R-CHOP in previously untreated DLBCL patients. The results indicated that the polatuzumab vedotin combination significantly improved progression-free survival over R-CHOP. ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2115304?utm_source=openai))

Additionally, the MAIN study (NCT00486759) investigated the addition of bevacizumab to R-CHOP in DLBCL patients. This study found that while bevacizumab increased cardiotoxicity, it did not improve progression-free survival compared to R-CHOP alone. ([haematologica.org](https://haematologica.org/article/view/7114?utm_source=openai))

These studies highlight ongoing efforts to enhance DLBCL treatment outcomes by modifying the standard R-CHOP regimen. ",NCT03274492,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Lenalidomide monotherapy when used to treat Myelodysplastic syndrome.
Output it in the format NCT<Number>",NCT01029262,The clinical trial that best describes the efficacy of lenalidomide monotherapy compared to placebo in treating myelodysplastic syndrome is identified by the ClinicalTrials.gov identifier NCT00179621. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21753188/?utm_source=openai)) ,NCT00179621,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin, Pegylated liposomal doxorubicin, Bevacizumab|Carboplatin and Gemcitabine (GCb) and Bevacizumab|Carboplatin and Paclitaxel (CP) and Bevacizumab compared to Carboplatin and Gemcitabine (GCb) when used to treat Ovarian cancer.
Output it in the format NCT<Number>",NCT01802749,"The clinical trial that best matches your description is identified by the ClinicalTrials.gov identifier NCT01837251. This Phase III trial evaluated the efficacy of two treatment regimens in patients with platinum-sensitive recurrent ovarian cancer:

- **Experimental Arm**: Carboplatin, Pegylated Liposomal Doxorubicin (PLD), and Bevacizumab
- **Standard Arm**: Carboplatin, Gemcitabine, and Bevacizumab

The study aimed to determine the optimal therapeutic index for these combinations. The trial was completed, with the primary completion date in January 2021. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT01837251/?utm_source=openai))

Another relevant study is NCT00565851, which investigated the combination of Carboplatin, Paclitaxel, and Gemcitabine Hydrochloride with or without Bevacizumab in treating patients with recurrent ovarian, epithelial, primary peritoneal, or fallopian tube cancer. This Phase III trial is active but not recruiting. ([trial.medpath.com](https://trial.medpath.com/clinical-trial/27fe2385b58248a5/nct00565851-carboplatin-paclitaxel-gemcitabine-bevacizumab-ovarian-cancer?utm_source=openai))

Additionally, NCT01739218 examined the combination of Carboplatin, Paclitaxel, and Bevacizumab in ovarian cancer. This study has been completed. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01739218?utm_source=openai))

These trials provide comprehensive insights into the efficacy of various chemotherapy combinations with Bevacizumab in the treatment of ovarian cancer. ",NCT01837251,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Lenalidomide monotherapy when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00405756,"The clinical trial that best describes the efficacy of lenalidomide monotherapy compared to placebo in treating multiple myeloma is identified by the ClinicalTrials.gov identifier NCT00114101. This randomized, double-blind, placebo-controlled, phase 3 trial investigated lenalidomide maintenance therapy versus placebo after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma. The study demonstrated that lenalidomide maintenance therapy significantly prolonged the time to disease progression and improved overall survival compared to placebo. ([nejm.org](https://www.nejm.org/doi/full/10.1056/nejmoa1114083?utm_source=openai)) ",NCT00114101,False,
"Find/search the clinical trial id that best describes the efficacy of Thalidomide and Dexamethasone (TD) compared to VTD when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00256776,"The clinical trial that best describes the efficacy of Thalidomide and Dexamethasone (TD) compared to Bortezomib, Thalidomide, and Dexamethasone (VTD) in treating multiple myeloma is registered under the identifier NCT01134484. This Phase 3 trial evaluated whether adding Bortezomib to the TD regimen increases the rate of complete and near-complete responses in patients with newly diagnosed multiple myeloma. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01134484?utm_source=openai)) ",NCT01134484,False,
"Find/search the clinical trial id that best describes the efficacy of Observation compared to Lenalidomide monotherapy when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00551928,The clinical trial that best describes the efficacy of observation compared to lenalidomide monotherapy in treating multiple myeloma is identified by the ClinicalTrials.gov identifier NCT01169337. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31652094/?utm_source=openai)) ,NCT01169337,False,
"Find/search the clinical trial id that best describes the efficacy of FLA compared to ADE (standard-dose Ara-C) when used to treat Acute myeloid leukemia.
Output it in the format NCT<Number>",NCT00005863,"The clinical trial that best describes the efficacy of FLA (fludarabine, cytarabine, and G-CSF) compared to ADE (cytarabine, daunorubicin, and etoposide) in treating acute myeloid leukemia is identified by the ClinicalTrials.gov identifier NCT00006069. ",NCT00006069,False,
"Find/search the clinical trial id that best describes the efficacy of ICE-V compared to CDE when used to treat Small cell lung cancer.
Output it in the format NCT<Number>",NCT00002822,"I couldn't locate a specific clinical trial comparing the efficacy of ICE-V to CDE in treating small cell lung cancer. It's possible that such a trial hasn't been conducted or isn't publicly registered. For the most accurate and up-to-date information, I recommend consulting the ClinicalTrials.gov database or discussing with a healthcare professional specializing in oncology. ",,False,
"Find/search the clinical trial id that best describes the efficacy of ABCM compared to Melphalan and Methylprednisolone when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00002599,"The clinical trial that best describes the efficacy of ABCM (adriamycin, BCNU, cyclophosphamide, and melphalan) compared to melphalan and methylprednisolone in treating multiple myeloma is identified by the ClinicalTrials.gov identifier NCT03217812. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37024420/?utm_source=openai)) ",NCT03217812,False,
"Find/search the clinical trial id that best describes the efficacy of mFOLFOX6 and Cetuximab compared to mFOLFOX6 when used to treat Colon cancer.
Output it in the format NCT<Number>",NCT00079274,The clinical trial that evaluates the efficacy of mFOLFOX6 combined with cetuximab compared to mFOLFOX6 alone in treating colon cancer is identified by the ClinicalTrials.gov identifier NCT04607421. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Encorafenib?utm_source=openai)) ,NCT04607421,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP) and Nivolumab compared to Carboplatin and Paclitaxel (CP) when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT03838159,"The clinical trial that best describes the efficacy of Carboplatin and Paclitaxel (CP) combined with Nivolumab compared to CP alone in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT02998528. This trial, known as CheckMate 816, evaluated the neoadjuvant treatment of resectable non-small cell lung cancer using Nivolumab plus platinum-doublet chemotherapy. ([ascopubs.org](https://ascopubs.org/doi/full/10.1200/JCO.22.02509?utm_source=openai)) ",NCT02998528,False,
"Find/search the clinical trial id that best describes the efficacy of Gemcitabine and Vinorelbine compared to Cisplatin and Vinorelbine (CVb) when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT00004100,"I couldn't locate a specific clinical trial with an NCT number that directly compares the efficacy of Gemcitabine and Vinorelbine (GV) to Cisplatin and Vinorelbine (CVb) in treating non-small cell lung cancer (NSCLC). However, several studies have explored related comparisons:

- **Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non–Small-Cell Lung Cancer**: This phase III trial assessed the quality of life and survival outcomes among different chemotherapy combinations in NSCLC patients. ([ascopubs.org](https://ascopubs.org/doi/abs/10.1200/JCO.2003.06.099?utm_source=openai))

- **Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer**: This study compared the efficacy and toxicity profiles of Vinorelbine-Cisplatin versus Gemcitabine-Cisplatin regimens. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2990234/?utm_source=openai))

- **Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer**: This trial evaluated whether adding Cisplatin to a Gemcitabine and Vinorelbine regimen improved overall survival in advanced NSCLC patients. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15197195/?utm_source=openai))

While these studies provide insights into various chemotherapy combinations for NSCLC, a direct comparison between GV and CVb regimens with a specific NCT identifier may not be available. ",,False,
"Find/search the clinical trial id that best describes the efficacy of Tamoxifen monotherapy compared to Placebo when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00002542,The clinical trial that best describes the efficacy of tamoxifen monotherapy compared to placebo in treating breast cancer is the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 study. This trial demonstrated that tamoxifen significantly reduces the incidence of breast cancer in high-risk women. The corresponding ClinicalTrials.gov identifier (NCT number) for this study is NCT00000654. ,NCT00000654,False,
"Find/search the clinical trial id that best describes the efficacy of ddEC-T compared to AC-T when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00014222,"The clinical trial that best describes the efficacy of dose-dense epirubicin and cyclophosphamide followed by paclitaxel (ddEC-T) compared to standard anthracycline and cyclophosphamide followed by taxane (AC-T) in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT00433420. This trial, known as the GIM-2 study, evaluated the effectiveness of dose-dense chemotherapy regimens in high-risk breast cancer patients. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4813643/?utm_source=openai)) ",NCT00433420,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Lapatinib (TL)|Lapatinib and Paclitaxel compared to Paclitaxel and Trastuzumab (TH) when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00667251,The clinical trial that best describes the efficacy of Docetaxel and Lapatinib (TL) compared to Paclitaxel and Trastuzumab (TH) in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT00450892. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25467016/?utm_source=openai)) ,NCT00450892,False,
"Find/search the clinical trial id that best describes the efficacy of Gemcitabine monotherapy compared to Erlotinib and Gemcitabine when used to treat Pancreatic cancer (Locally Advanced or Unresectable or Metastatic).
Output it in the format NCT<Number>",NCT00026338,"The clinical trial that best describes the efficacy of gemcitabine monotherapy compared to the combination of erlotinib and gemcitabine in treating locally advanced, unresectable, or metastatic pancreatic cancer is identified by the ClinicalTrials.gov identifier NCT00026338. This Phase III trial, conducted by the National Cancer Institute of Canada Clinical Trials Group, demonstrated a statistically significant improvement in overall survival for patients receiving the combination therapy over those receiving gemcitabine alone. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17452677/?utm_source=openai)) ",NCT00026338,True,
"Find/search the clinical trial id that best describes the efficacy of ADT compared to ADT and RT when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT00002633,The clinical trial that best describes the efficacy of androgen-deprivation therapy (ADT) compared to ADT combined with radiotherapy (RT) in treating prostate cancer is registered under the identifier NCT00002633. This randomized controlled trial demonstrated that adding RT to ADT significantly improves overall survival and reduces deaths from prostate cancer in men with locally advanced disease. ([ascopubs.org](https://ascopubs.org/doi/full/10.1200/JCO.2014.57.7510?utm_source=openai)) ,NCT00002633,True,
"Find/search the clinical trial id that best describes the efficacy of CMF compared to Observation when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00002582,"I couldn't locate a specific clinical trial with an NCT number that directly compares CMF chemotherapy to observation in breast cancer treatment. However, CMF (Cyclophosphamide, Methotrexate, and Fluorouracil) has been extensively studied in the adjuvant treatment of breast cancer. Many trials have evaluated its efficacy, often comparing it to other chemotherapy regimens or assessing its benefits over no adjuvant therapy.

For detailed information on such studies, you might consider searching the ClinicalTrials.gov database using keywords like ""CMF,"" ""breast cancer,"" and ""observation."" This approach can help you identify relevant trials and their outcomes. ",,False,
"Find/search the clinical trial id that best describes the efficacy of CHOP (Prednisolone) compared to BCHOP when used to treat Mantle cell lymphoma.
Output it in the format NCT<Number>",NCT00513955,"The clinical trial that best describes the efficacy of CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) compared to R-CHOP (CHOP plus Rituximab) in treating mantle cell lymphoma is identified by the ClinicalTrials.gov identifier NCT00209209. This trial, conducted by the German Low-Grade Lymphoma Study Group, demonstrated that adding Rituximab to CHOP significantly improved overall survival in patients with mantle cell lymphoma. ([link.springer.com](https://link.springer.com/article/10.1007/s00277-023-05385-1?utm_source=openai)) ",NCT00209209,False,
"Find/search the clinical trial id that best describes the efficacy of ATG (Horse) and Cyclosporine compared to ATG (Rabbit) and Cyclosporine when used to treat Aplastic anemia.
Output it in the format NCT<Number>",NCT00260689,The clinical trial that best describes the efficacy of horse-derived antithymocyte globulin (ATG) and cyclosporine compared to rabbit-derived ATG and cyclosporine in treating aplastic anemia is registered under the identifier NCT00260689. ([nejm.org](https://www.nejm.org/doi/10.1056/NEJMoa1103975?utm_source=openai)) ,NCT00260689,True,
"Find/search the clinical trial id that best describes the efficacy of No induction compared to Bortezomib and Dexamethasone (Vd) when used to treat Light-chain (AL) amyloidosis.
Output it in the format NCT<Number>",NCT01998503,"The clinical trial that best describes the efficacy of no induction therapy compared to Bortezomib and Dexamethasone (Vd) in treating Light-chain (AL) amyloidosis is identified by the ClinicalTrials.gov identifier NCT01277016. This Phase III trial, conducted by the European Myeloma Network, randomized untreated patients with systemic AL amyloidosis to receive either Melphalan and Dexamethasone (MDex) or Bortezomib, Melphalan, and Dexamethasone (BMDex). ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT01277016/?utm_source=openai)) ",NCT01277016,False,
"Find/search the clinical trial id that best describes the efficacy of Bortezomib monotherapy compared to Observation when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00417911,The clinical trial that best describes the efficacy of bortezomib monotherapy compared to observation in treating multiple myeloma is identified by the ClinicalTrials.gov identifier NCT00416208. This randomized phase III study investigated bortezomib consolidation therapy versus observation in patients with newly diagnosed multiple myeloma post-transplant. ([ascopubs.org](https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.8511?utm_source=openai)) ,NCT00416208,False,
"Find/search the clinical trial id that best describes the efficacy of TAC (Docetaxel) compared to AC-D when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00003782,"I couldn't locate a specific clinical trial with an NCT number that directly compares TAC (Docetaxel) to AC-D in the treatment of breast cancer. However, there are studies that have evaluated the efficacy of these regimens:

- **TAC Regimen**: This combination includes Docetaxel, Doxorubicin, and Cyclophosphamide.

- **AC-D Regimen**: This involves Doxorubicin and Cyclophosphamide followed by Docetaxel.

One notable study is the BCIRG 005 trial, which compared TAC to AC followed by Docetaxel in early-stage breast cancer patients. The results indicated that both regimens were effective, with some differences in toxicity profiles.

For more detailed information, you might consider searching clinical trial databases or consulting recent oncology literature. ",,False,
"Find/search the clinical trial id that best describes the efficacy of AC-TH (Paclitaxel) compared to AC-THL (Paclitaxel) when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00486668,"I couldn't locate a specific clinical trial with an NCT number that directly compares the efficacy of AC-TH (Paclitaxel) to AC-THL (Paclitaxel) in the treatment of breast cancer. It's possible that such a trial may not exist or isn't registered under a publicly accessible NCT number. For the most accurate and up-to-date information, I recommend consulting the ClinicalTrials.gov database or discussing with a healthcare professional who specializes in oncology. ",,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Erlotinib compared to Docetaxel monotherapy when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT02775006,"The clinical trial that best describes the efficacy of docetaxel and erlotinib compared to docetaxel monotherapy in treating non-small cell lung cancer (NSCLC) is the DELTA trial. This randomized phase III study investigated the efficacy of erlotinib versus docetaxel in previously treated patients with advanced NSCLC in an EGFR-unselected patient population. The trial concluded that erlotinib failed to show an improvement in progression-free survival or overall survival compared with docetaxel. ([ascopubs.org](https://ascopubs.org/doi/full/10.1200/JCO.2013.52.4694?utm_source=openai))

However, the specific ClinicalTrials.gov identifier (NCT number) for the DELTA trial is not readily available in the provided sources. To obtain the NCT number, you may search the ClinicalTrials.gov database using the trial's title or principal investigator's name. ",,False,
"Find/search the clinical trial id that best describes the efficacy of EC-ddT compared to ddT-EC when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00070278,"I'm unable to locate a specific clinical trial with an NCT number that directly compares the efficacy of EC-ddT (Epirubicin and Cyclophosphamide followed by dose-dense Docetaxel) versus ddT-EC (dose-dense Docetaxel followed by Epirubicin and Cyclophosphamide) in the treatment of breast cancer. It's possible that such a study has not been conducted or is not registered in publicly accessible databases.

For the most accurate and up-to-date information, I recommend consulting clinical trial registries such as ClinicalTrials.gov or reaching out to a healthcare professional specializing in oncology. They can provide guidance on current research and treatment protocols relevant to your specific situation. ",,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Sintilimab monotherapy when used to treat Non-small cell lung cancer squamous.
Output it in the format NCT<Number>",NCT03150875,The clinical trial that evaluates the efficacy of docetaxel monotherapy compared to sintilimab monotherapy in treating advanced or metastatic squamous non-small-cell lung cancer is registered under the identifier NCT03150875. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36336841/?utm_source=openai)) ,NCT03150875,True,
"Find/search the clinical trial id that best describes the efficacy of Rituximab monotherapy compared to Observation when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT00718549,"I couldn't locate a clinical trial specifically comparing Rituximab monotherapy to observation in the treatment of chronic lymphocytic leukemia (CLL). However, Rituximab is commonly used in combination with other therapies for CLL. For instance, the clinical trial NCT00281918 evaluated the efficacy of Rituximab in combination with Fludarabine and Cyclophosphamide in treating CLL.

If you're interested in exploring more about Rituximab's role in CLL treatment, I recommend consulting clinical trial registries or discussing with a healthcare professional for the most current and relevant information. ",NCT00281918,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin, Pemetrexed, Amivantamab compared to Carboplatin and Pemetrexed when used to treat Non-small cell lung cancer (Locally Advanced or Metastatic).
Output it in the format NCT<Number>",NCT04538664,"The clinical trial that best describes the efficacy of Carboplatin, Pemetrexed, and Amivantamab compared to Carboplatin and Pemetrexed in treating locally advanced or metastatic non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT04988295. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19?utm_source=openai)) ",NCT04988295,False,
"Find/search the clinical trial id that best describes the efficacy of RVD compared to Dara-RVd (SC daratumumab) when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT03710603,"The clinical trial that best describes the efficacy of RVD (lenalidomide, bortezomib, and dexamethasone) compared to Dara-RVd (subcutaneous daratumumab combined with RVD) in treating multiple myeloma is the PERSEUS trial, registered under the identifier NCT03710603. ([oncnursingnews.com](https://www.oncnursingnews.com/view/subcutaneous-daratumumab-plus-vrd-seeks-fda-approval-for-transplant-eligible-multiple-myeloma?utm_source=openai)) ",NCT03710603,True,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Trastuzumab (TH) and Pyrotinib compared to Docetaxel and Trastuzumab (TH) when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT03588091,"The clinical trial that best describes the efficacy of combining Docetaxel, Trastuzumab, and Pyrotinib compared to Docetaxel and Trastuzumab alone in treating breast cancer is registered under the identifier NCT03588091. This phase 3 trial, known as PHEDRA, evaluated the neoadjuvant use of Pyrotinib, Trastuzumab, and Docetaxel in patients with HER2-positive breast cancer. The study demonstrated a significant improvement in the total pathological complete response (tpCR) rate for the combination therapy compared to the placebo group. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36575513/?utm_source=openai)) ",NCT03588091,True,
"Find/search the clinical trial id that best describes the efficacy of Gemcitabine monotherapy compared to Adavosertib and Gemcitabine when used to treat Ovarian cancer.
Output it in the format NCT<Number>",NCT02101775,The clinical trial that best describes the efficacy of Gemcitabine monotherapy compared to the combination of Adavosertib and Gemcitabine in treating ovarian cancer is registered under the identifier NCT02151292. ([ascopubs.org](https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.5518?utm_source=openai)) ,NCT02151292,False,
"Find/search the clinical trial id that best describes the efficacy of Pomalidomide and Dexamethasone (Pd) compared to PCD when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01432600,"The clinical trial that best describes the efficacy of Pomalidomide and Dexamethasone (Pd) compared to Pomalidomide, Cyclophosphamide, and Dexamethasone (PCD) in treating multiple myeloma is registered under the identifier NCT03143049. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT03143049?utm_source=openai)) ",NCT03143049,False,
"Find/search the clinical trial id that best describes the efficacy of R-CHOP compared to Pola-R-CHP when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT03274492,The clinical trial that best describes the efficacy of R-CHOP compared to Pola-R-CHP in treating diffuse large B-cell lymphoma is identified by the ClinicalTrials.gov identifier NCT03274492. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34904799/?utm_source=openai)) ,NCT03274492,True,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel, Enzalutamide, Prednisolone compared to Docetaxel and Prednisolone when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT02288247,"The STAMPEDE trial (NCT00268476) is a comprehensive study evaluating various treatment combinations for prostate cancer. One of its arms, Arm J, investigates the efficacy of standard care plus abiraterone, enzalutamide, and prednisolone. However, there isn't a specific arm within this trial that directly compares the combination of docetaxel, enzalutamide, and prednisolone to docetaxel and prednisolone. Therefore, a clinical trial with the exact comparison you're seeking may not be available. ",NCT00268476,False,
"Find/search the clinical trial id that best describes the efficacy of ADT compared to ADT, Abiraterone, Apalutamide when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT03009981,"The clinical trial that best describes the efficacy of androgen deprivation therapy (ADT) compared to ADT combined with abiraterone acetate (AAP) or apalutamide in treating prostate cancer is registered under the identifier NCT02867020. This Phase II randomized study, known as LACOG 0415, evaluated the use of AAP plus ADT versus apalutamide alone versus AAP plus apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34655838/?utm_source=openai)) ",NCT02867020,False,
"Find/search the clinical trial id that best describes the efficacy of Crizotinib monotherapy compared to Carboplatin and Pemetrexed when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT01639001,"The clinical trial that best describes the efficacy of Crizotinib monotherapy compared to Carboplatin and Pemetrexed in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT01154140. This Phase 3 study, known as PROFILE 1014, demonstrated that Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive non-small-cell lung cancer. ([nejm.org](https://www.nejm.org/doi/10.1056/nejmoa1408440?utm_source=openai)) ",NCT01154140,False,
"Find/search the clinical trial id that best describes the efficacy of CHUT compared to Observation when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00002870,The clinical trial that best describes the efficacy of CHUT (Chemotherapy plus Pembrolizumab) compared to Observation in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT05812807. This Phase III trial evaluates the effect of pembrolizumab versus observation in patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy combined with pembrolizumab. ([careacross.com](https://www.careacross.com/clinical-trials/trial/NCT05812807?utm_source=openai)) ,NCT05812807,False,
"Find/search the clinical trial id that best describes the efficacy of Paclitaxel and Ramucirumab compared to Paclitaxel monotherapy when used to treat Gastric cancer.
Output it in the format NCT<Number>",NCT02898077,"The clinical trial that best describes the efficacy of Paclitaxel combined with Ramucirumab compared to Paclitaxel monotherapy in treating gastric cancer is identified by the ClinicalTrials.gov identifier NCT01170663. This Phase III randomized, multicenter, double-blind, placebo-controlled trial, known as the RAINBOW study, evaluated the safety and efficacy of Paclitaxel plus Ramucirumab versus Paclitaxel plus placebo in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. ([ctv.veeva.com](https://ctv.veeva.com/study/a-study-of-paclitaxel-with-or-without-ramucirumab-imc-1211b-in-metastatic-gastric-adenocarcinoma?utm_source=openai)) ",NCT01170663,False,
"Find/search the clinical trial id that best describes the efficacy of 7 plus 3d and Midostaurin compared to 7 plus 3d when used to treat Acute myeloid leukemia.
Output it in the format NCT<Number>",NCT00651261,The clinical trial that best describes the efficacy of the 7+3 regimen combined with midostaurin compared to the 7+3 regimen alone in treating acute myeloid leukemia is identified by the ClinicalTrials.gov identifier NCT00651261. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28644114/?utm_source=openai)) ,NCT00651261,True,
"Find/search the clinical trial id that best describes the efficacy of FCR compared to Cyclophosphamide and Fludarabine (FC) when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT00090051,"The clinical trial that best describes the efficacy of fludarabine, cyclophosphamide, and rituximab (FCR) compared to fludarabine and cyclophosphamide (FC) in treating chronic lymphocytic leukemia (CLL) is identified by the ClinicalTrials.gov identifier NCT00281918. This trial, known as the CLL8 study, demonstrated that FCR therapy significantly improved progression-free survival and overall survival compared to FC in previously untreated patients with CLL. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26486789/?utm_source=openai)) ",NCT00281918,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Lenalidomide monotherapy when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT01122472,"I couldn't find a clinical trial that directly compares lenalidomide monotherapy to a placebo in the treatment of diffuse large B-cell lymphoma (DLBCL). However, lenalidomide has been evaluated in various clinical trials for DLBCL, often in combination with other therapies. For instance, the REMARC trial (NCT01122472) assessed lenalidomide maintenance therapy versus placebo in elderly patients with DLBCL who achieved a response after first-line therapy. Additionally, the ROBUST trial (NCT02285062) evaluated lenalidomide in combination with R-CHOP chemotherapy in patients with untreated ABC-type DLBCL.

While these studies provide insights into lenalidomide's role in DLBCL treatment, a direct comparison between lenalidomide monotherapy and placebo in this context appears to be lacking. ",NCT01122472,True,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Docetaxel and Ramucirumab when used to treat Non-small cell lung cancer (Metastatic).
Output it in the format NCT<Number>",NCT01168973,The clinical trial that best describes the efficacy of Docetaxel monotherapy compared to Docetaxel combined with Ramucirumab in treating metastatic non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT01703091. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01703091?utm_source=openai)) ,NCT01703091,False,
"Find/search the clinical trial id that best describes the efficacy of R-CHOP-14 compared to CHOP-14 when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT00052936,"I couldn't locate a clinical trial with an NCT number that directly compares the efficacy of R-CHOP-14 versus CHOP-14 in treating Diffuse Large B-Cell Lymphoma (DLBCL). However, a notable study published in the New England Journal of Medicine compared CHOP chemotherapy plus rituximab (R-CHOP) with CHOP alone in elderly patients with DLBCL. This study demonstrated that the addition of rituximab to CHOP significantly improved complete response rates and overall survival without a significant increase in toxicity. ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa011795?utm_source=openai))

Additionally, a phase III trial compared R-CHOP administered every 14 days (R-CHOP-14) with R-CHOP administered every 21 days (R-CHOP-21) in newly diagnosed DLBCL patients. The study found that R-CHOP-14 could be delivered as effectively as R-CHOP-21, with comparable levels of acute toxicity. ([ascopubs.org](https://ascopubs.org/doi/10.1200/jco.2009.27.15_suppl.8506?utm_source=openai))

While these studies provide valuable insights into the treatment of DLBCL, they do not specifically address the comparison between R-CHOP-14 and CHOP-14. ",,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Docetaxel and Ramucirumab when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00703326,"I couldn't locate a clinical trial specifically comparing docetaxel monotherapy to the combination of docetaxel and ramucirumab in breast cancer treatment. However, there is a relevant study, identified as NCT00703326, which evaluated the efficacy of docetaxel with or without ramucirumab in patients with locally recurrent or metastatic breast cancer. This phase II trial aimed to assess the potential benefits of adding ramucirumab to docetaxel therapy.

For more detailed information about this study, you can visit the ClinicalTrials.gov page:

Please note that clinical trial identifiers are subject to change, and it's advisable to consult the latest resources or a healthcare professional for the most current information. ",NCT00703326,True,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin, Cetuximab, RT compared to Cisplatin and RT when used to treat Head and neck cancer.
Output it in the format NCT<Number>",NCT00084318,"The clinical trial that best describes the efficacy of cisplatin and radiotherapy (RT) compared to cetuximab and RT in treating head and neck cancer is identified by the ClinicalTrials.gov identifier NCT01302834. This trial, known as NRG Oncology RTOG 1016, was a randomized, multicenter, non-inferiority study focusing on human papillomavirus-positive oropharyngeal cancer. The results indicated that radiotherapy combined with cetuximab was inferior to radiotherapy combined with cisplatin in terms of overall survival and progression-free survival. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30449625/?utm_source=openai)) ",NCT01302834,False,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide and Rituximab (R2) compared to Rituximab monotherapy when used to treat Follicular lymphoma.
Output it in the format NCT<Number>",NCT01307605,"The clinical trial that best describes the efficacy of Lenalidomide and Rituximab (R2) compared to Rituximab monotherapy in treating follicular lymphoma is identified by the ClinicalTrials.gov identifier NCT01938001. This phase III trial, known as AUGMENT, evaluated the combination of Lenalidomide and Rituximab versus Rituximab alone in patients with relapsed or refractory indolent non-Hodgkin's lymphoma, including follicular lymphoma. ",NCT01938001,False,
"Find/search the clinical trial id that best describes the efficacy of Fulvestrant monotherapy compared to Taselisib and Fulvestrant when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT02340221,"The clinical trial that best describes the efficacy of fulvestrant monotherapy compared to the combination of taselisib and fulvestrant in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT02340221. This Phase III, double-blind, placebo-controlled, randomized study, known as the SANDPIPER trial, evaluated the combination of taselisib and fulvestrant versus placebo and fulvestrant in postmenopausal women with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, locally advanced or metastatic breast cancer. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT02340221?utm_source=openai)) ",NCT02340221,True,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Regorafenib monotherapy when used to treat Osteosarcoma.
Output it in the format NCT<Number>",NCT02048371,The clinical trial that best describes the efficacy of placebo compared to regorafenib monotherapy in treating osteosarcoma is identified by the ClinicalTrials.gov identifier NCT02048371. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31013172/?utm_source=openai)) ,NCT02048371,True,
"Find/search the clinical trial id that best describes the efficacy of CMF compared to CMF and RT|E-CMF and RT|A-CMF and RT|MMM and RT when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00003893,"The clinical trial that best describes the efficacy of CMF (Cyclophosphamide, Methotrexate, and Fluorouracil) compared to CMF combined with radiotherapy (RT), E-CMF (Epirubicin plus CMF) with RT, A-CMF (Adriamycin plus CMF) with RT, and MMM (Mitoxantrone, Methotrexate, and Mitomycin-C) with RT in the treatment of breast cancer is identified by the ClinicalTrials.gov number NCT00003577. ([nejm.org](https://www.nejm.org/doi/10.1056/NEJMoa052084?utm_source=openai))

This trial, known as the National Epirubicin Adjuvant Trial (NEAT), evaluated the addition of epirubicin to CMF chemotherapy in early breast cancer. The study demonstrated that the combination of epirubicin and CMF was superior to CMF alone as adjuvant treatment for early breast cancer. ([nejm.org](https://www.nejm.org/doi/10.1056/NEJMoa052084?utm_source=openai))

Additionally, the International Standard Randomised Controlled Trial Number (ISRCTN) 92834934 corresponds to a study comparing CMF and MMM chemotherapy regimens in patients with metastatic breast cancer. ([isrctn.com](https://www.isrctn.com/ISRCTN92834934?utm_source=openai))

However, specific clinical trials directly comparing all the mentioned regimens (CMF, CMF+RT, E-CMF+RT, A-CMF+RT, and MMM+RT) in breast cancer treatment are not readily available. The above trials provide insights into some of these comparisons, but a comprehensive trial encompassing all these specific combinations may not exist. ",NCT00003577,False,
"Find/search the clinical trial id that best describes the efficacy of Bendamustine and Rituximab (BR) compared to Bendamustine and Rituximab (BR) and Ibrutinib when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT01776840,The clinical trial that best describes the efficacy of Bendamustine and Rituximab (BR) compared to BR combined with Ibrutinib in treating Chronic Lymphocytic Leukemia is identified by the ClinicalTrials.gov identifier NCT01611090. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01611090?utm_source=openai)) ,NCT01611090,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Observation when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT00376792,"The clinical trial that best describes the efficacy of docetaxel monotherapy compared to observation in treating prostate cancer is identified by the ClinicalTrials.gov identifier NCT00376792. ([ctv.veeva.com](https://ctv.veeva.com/study/docetaxel-compared-with-observation-in-treating-patients-who-have-undergone-radical-prostatectomy-fo?utm_source=openai))

This randomized phase III trial, conducted by the Scandinavian Prostate Cancer Group, aimed to compare the time to prostate-specific antigen (PSA) progression in patients with margin-positive tumors after undergoing radical prostatectomy for high-grade prostate cancer, treated with docetaxel versus observation. ([ctv.veeva.com](https://ctv.veeva.com/study/docetaxel-compared-with-observation-in-treating-patients-who-have-undergone-radical-prostatectomy-fo?utm_source=openai))

The study enrolled 396 patients and assessed outcomes such as PSA doubling time, quality of life, overall survival, and metastasis-free survival. ([ctv.veeva.com](https://ctv.veeva.com/study/docetaxel-compared-with-observation-in-treating-patients-who-have-undergone-radical-prostatectomy-fo?utm_source=openai)) ",NCT00376792,True,
"Find/search the clinical trial id that best describes the efficacy of EP-T compared to EC-T when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT01026116,"I couldn't locate a specific clinical trial comparing the efficacy of EP-T (Epirubicin, Paclitaxel) versus EC-T (Epirubicin, Cyclophosphamide, Paclitaxel) in the treatment of breast cancer. It's possible that such a trial hasn't been conducted or isn't publicly registered. For the most accurate and up-to-date information, I recommend consulting clinical trial registries like ClinicalTrials.gov or speaking with a healthcare professional specializing in oncology. ",,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Gefitinib monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT00020709,"The clinical trial that best describes the efficacy of placebo compared to gefitinib monotherapy in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT00049543. This study, known as the NCIC CTG BR19 trial, was a phase III, randomized, placebo-controlled trial evaluating the impact of adjuvant gefitinib on overall survival in patients with completely resected non-small-cell lung cancer. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23980091/?utm_source=openai)) ",NCT00049543,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Gemcitabine monotherapy when used to treat Bladder cancer.
Output it in the format NCT<Number>",NCT00445601,"I couldn't locate a clinical trial that directly compares the efficacy of placebo versus gemcitabine monotherapy in treating bladder cancer. However, a notable study investigated the addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin chemotherapy in patients with locally advanced muscle-invasive bladder cancer. This trial is registered under EudraCT number 2012-004895-01 and ISRCTN number 56349930. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35421369/?utm_source=openai))

Additionally, a systematic review and meta-analysis examined the role of a single postoperative instillation of gemcitabine compared to placebo in patients with non-muscle-invasive bladder cancer. This analysis included studies such as the one by Messing et al., which reported a recurrence rate of 35% in the gemcitabine group versus 47% in the placebo group, indicating a statistically significant difference favoring gemcitabine. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9140686/?utm_source=openai))

While these studies provide insights into the use of gemcitabine in bladder cancer treatment, they do not specifically address gemcitabine monotherapy compared to placebo. ",,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Estramustine compared to Mitoxantrone and Prednisone when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT00004001,"The clinical trial that best describes the efficacy of docetaxel and estramustine compared to mitoxantrone and prednisone in treating prostate cancer is identified by the ClinicalTrials.gov identifier NCT00004001. This randomized phase III trial evaluated the effectiveness of these treatment combinations in patients with metastatic, hormone-independent prostate cancer. ([nejm.org](https://www.nejm.org/doi/full/10.1056/nejmoa041318?utm_source=openai)) ",NCT00004001,True,
"Find/search the clinical trial id that best describes the efficacy of Best supportive care compared to Trabectedin monotherapy when used to treat Soft tissue sarcoma.
Output it in the format NCT<Number>",NCT02672527,"The clinical trial that best describes the efficacy of trabectedin monotherapy compared to best supportive care in treating soft tissue sarcoma is identified by the ClinicalTrials.gov identifier NCT02738887. This randomized phase III trial, known as the T-SAR study, was conducted by the French Sarcoma Group. It assessed the efficacy, safety, and quality of life of trabectedin versus best supportive care in patients with advanced soft tissue sarcoma who had progressed after 1-3 prior treatment lines. The study found that trabectedin demonstrated superior disease control without impairing quality of life, particularly in patients with liposarcoma and leiomyosarcoma. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33932507/?utm_source=openai)) ",NCT02738887,False,
"Find/search the clinical trial id that best describes the efficacy of Everolimus and Tamoxifen compared to Tamoxifen monotherapy when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT01298713,The clinical trial that best describes the efficacy of Everolimus combined with Tamoxifen compared to Tamoxifen monotherapy in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT01298713. ([ascopubs.org](https://ascopubs.org/doi/10.1200/JCO.2011.39.0708?utm_source=openai)) ,NCT01298713,True,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP), Bevacizumab, Nivolumab compared to Carboplatin and Paclitaxel (CP) and Bevacizumab when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT03117049,The clinical trial that evaluates the efficacy of Carboplatin and Paclitaxel (CP) with Bevacizumab and Nivolumab compared to CP with Bevacizumab in treating nonsquamous non-small cell lung cancer is registered under the identifier NCT03117049. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37641544/?utm_source=openai)) ,NCT03117049,True,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Paclitaxel monotherapy when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00002662,The clinical trial that best describes the efficacy of docetaxel monotherapy compared to paclitaxel monotherapy in treating breast cancer is registered under the identifier NCT00002662. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00002662?utm_source=openai)) ,NCT00002662,True,
"Find/search the clinical trial id that best describes the efficacy of Observation compared to Docetaxel monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT01038661,"The clinical trial that best describes the efficacy of observation compared to docetaxel monotherapy in treating non-small cell lung cancer is identified by the ClinicalTrials.gov identifier NCT00863512. This randomized phase III trial investigated various chemotherapy regimens, including docetaxel, against observation in patients with early-stage non-small cell lung cancer. ([ctv.veeva.com](https://ctv.veeva.com/study/chemotherapy-or-observation-in-treating-patients-with-early-stage-non-small-cell-lung-cancer?utm_source=openai)) ",NCT00863512,False,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide and Dexamethasone (Rd) compared to IRd when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01564537,"The clinical trial that best describes the efficacy of Lenalidomide and Dexamethasone (Rd) compared to Ixazomib, Lenalidomide, and Dexamethasone (IRd) in treating multiple myeloma is identified by the ClinicalTrials.gov identifier NCT02253316. ([clinicaltrials.ucsf.edu](https://clinicaltrials.ucsf.edu/trial/NCT02253316?utm_source=openai))

This Phase II study evaluates the IRd regimen following autologous stem cell transplantation, with subsequent maintenance therapy using either Ixazomib or Lenalidomide. The trial began in January 2015 and is expected to be completed by August 2025. The primary objective is to assess the progression-free survival and overall survival benefits of the IRd regimen compared to Rd in patients with multiple myeloma.

Additionally, a real-world study published in 2021 reported that the IRd regimen resulted in a median progression-free survival of 17.5 months, compared to 11.5 months for the Rd regimen, indicating a significant improvement with the addition of Ixazomib. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7810195/?utm_source=openai)) ",NCT02253316,False,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide and Dexamethasone (Rd) compared to IRd when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01850524,"The clinical trial that best describes the efficacy of Lenalidomide and Dexamethasone (Rd) compared to Ixazomib, Lenalidomide, and Dexamethasone (IRd) in treating multiple myeloma is identified by the ClinicalTrials.gov identifier NCT01564537. This trial, known as the TOURMALINE-MM1 study, evaluated the addition of ixazomib to the Rd regimen in patients with relapsed and refractory multiple myeloma. The results demonstrated that the IRd regimen improved progression-free survival compared to Rd alone. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7810195/?utm_source=openai)) ",NCT01564537,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Trastuzumab (TH)|Paclitaxel and Trastuzumab (TH) compared to Vinorelbine and Trastuzumab (VH) when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00146549,The clinical trial that best describes the efficacy of Docetaxel and Trastuzumab (TH) compared to Vinorelbine and Trastuzumab (VH) in treating breast cancer is identified by the ClinicalTrials.gov identifier NCT00593697. ,NCT00593697,False,
"Find/search the clinical trial id that best describes the efficacy of Observation compared to CVP when used to treat Follicular lymphoma.
Output it in the format NCT<Number>",NCT00115700,"The clinical trial that best describes the efficacy of observation compared to CVP (cyclophosphamide, vincristine, and prednisone) in treating follicular lymphoma is identified by the ClinicalTrials.gov identifier NCT00075946. This study, conducted by the Eastern Cooperative Oncology Group (ECOG), evaluated the impact of maintenance therapy with rituximab versus observation after initial treatment with CVP chemotherapy in patients with previously untreated, advanced-stage follicular lymphoma. The results demonstrated that rituximab maintenance therapy significantly prolonged progression-free survival compared to observation alone. ([haematologica.org](https://haematologica.org/article/view/4477?utm_source=openai)) ",NCT00075946,False,
"Find/search the clinical trial id that best describes the efficacy of Azacitidine monotherapy compared to Azacitidine and Venetoclax when used to treat Acute myeloid leukemia.
Output it in the format NCT<Number>",NCT02993523,The clinical trial that best describes the efficacy of azacitidine monotherapy compared to azacitidine combined with venetoclax in treating acute myeloid leukemia is identified by the ClinicalTrials.gov identifier NCT02993523. ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2012971?query=featured_home&utm_source=openai)) ,NCT02993523,True,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Aspirin monotherapy when used to treat Venous thromboembolism.
Output it in the format NCT<Number>",NCT00222677,"The clinical trial that best describes the efficacy of placebo compared to aspirin monotherapy in treating venous thromboembolism is the ASPIRE trial. This study evaluated the use of low-dose aspirin (100 mg daily) versus placebo in patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism. The trial is registered under the Australian New Zealand Clinical Trials Registry number ACTRN12605000004662. ([nejm.org](https://www.nejm.org/doi/10.1056/NEJMoa1210384?utm_source=openai))

Additionally, the WARFASA trial investigated a similar comparison and is registered with ClinicalTrials.gov under the identifier NCT00222677. ([nejm.org](https://www.nejm.org/doi/full/10.1056/nejmoa1114238?utm_source=openai)) ",NCT00222677,True,
"Find/search the clinical trial id that best describes the efficacy of T-DM1 and ET compared to Trastuzumab and ET when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT01817452,"The clinical trial that best describes the efficacy of T-DM1 (trastuzumab emtansine) combined with endocrine therapy (ET) compared to trastuzumab with ET in treating HER2-positive, hormone receptor-positive breast cancer is registered under the identifier NCT01745965. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01745965?utm_source=openai))

This phase 2 trial, part of the ADAPT protocol, is a prospective, randomized, multicenter, open-label study. It evaluates preoperative T-DM1 with or without standard endocrine therapy versus trastuzumab with standard endocrine therapy over a 12-week period in patients with operable HER2-positive, hormone receptor-positive breast cancer. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01745965?utm_source=openai))

The primary outcome measure is the pathologic complete response (pCR) rate after 12 weeks of treatment. Secondary outcomes include dynamic testing based on proliferation and apoptosis changes in serial biopsies and imaging by MRI after three weeks of treatment, as well as evaluations of event-free survival, overall survival, toxicity, cardiac safety, overall safety, and health-related quality of life over a five-year period. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01745965?utm_source=openai))

The study began in November 2012, with an actual primary completion date in February 2015 and an anticipated study completion date in October 2024. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01745965?utm_source=openai)) ",NCT01745965,False,
"Find/search the clinical trial id that best describes the efficacy of VAD compared to Z-Dex when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00006232,"I couldn't locate a clinical trial with a specific identifier (NCT number) that directly compares the efficacy of VAD (vincristine, adriamycin, dexamethasone) to Z-Dex (oral idarubicin and dexamethasone) in treating multiple myeloma. However, a Phase I/II study investigated Z-Dex as an oral equivalent to VAD for initial therapy in multiple myeloma patients. This study reported an overall response rate of 70%, with 5% achieving complete remission. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8703828/?utm_source=openai))

Additionally, a Phase III randomized trial (NCT00215943) compared thalidomide and dexamethasone to VAD as induction chemotherapy for newly diagnosed multiple myeloma patients. While this study doesn't directly compare VAD to Z-Dex, it provides insights into the efficacy of VAD in the context of multiple myeloma treatment. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00215943?utm_source=openai))

For more detailed information, you can refer to the respective study publications and ClinicalTrials.gov entries. ",NCT00215943,False,
"Find/search the clinical trial id that best describes the efficacy of ddT-ddEC compared to nP-ddEC when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT01779206,"I'm unable to locate a clinical trial with an NCT number that directly compares the efficacy of ddT-ddEC to nP-ddEC in the treatment of breast cancer. It's possible that such a trial has not been conducted or is not registered under a publicly accessible NCT number. If you have any other questions or need information on related topics, feel free to ask. ",,False,
"Find/search the clinical trial id that best describes the efficacy of ADT and Zoledronic acid compared to ADT when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT00685646,The clinical trial that best describes the efficacy of androgen deprivation therapy (ADT) combined with zoledronic acid compared to ADT alone in treating prostate cancer is identified by the ClinicalTrials.gov identifier NCT00171639. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00171639?utm_source=openai)) ,NCT00171639,False,
